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reamble
his document has been developed by the American Col-
ege of Cardiology Foundation (ACCF) Task Force on
xpert Consensus Documents (ECDs), and was cospon-
ored by the American Heart Association (AHA). Expert
onsensus Documents are intended to inform practitioners
nd other interested parties of the opinion of the ACCF and
osponsors concerning evolving areas of clinical practice
nd/or technologies that are widely available or new to the
ractice community. Topics chosen for coverage by expert
onsensus documents are so designed because the evidence
ase, the experience with technology, and/or the clinical
ractice are not considered sufficiently well developed to be
valuated by the formal ACCF/AHA practice guidelines
rocess. Often the topic is the subject of ongoing investi-
ation. Thus, the reader should view the ECD as the best
ttempt of the ACCF and the cosponsors to inform and
uide clinical practice in areas where rigorous evidence may
ot be available or the evidence to date is not widely
ccepted. When feasible, ECDs include indications or
ontraindications. Some topics covered by ECDs will be
ddressed subsequently by the ACCF/AHA Practice
uidelines Committee.
Because the development of expert consensus documents
epends on the knowledge and experience of experts and
nvestigators in the field, many of whom have relationships
ith industry (RWI), the policy addressing writing com-
ittee members’ RWI must be realistic, workable, and
mplemented in a way that protects the integrity of the
rocess while allowing an open and honest exchange of the
ost up-to-date information. Every possible effort is made
o formulate a writing committee with a reasonable balance
f RWI. Specifically, all members of the writing panel are
sked to provide disclosure statements of all relationships
hat might be perceived as real or potential conflicts of
nterest. Participation in the writing committee is depen-
ent on a review of all relevant RWI by the task force to
nsure balance so that fair and unbiased consensus can be
eached. In addition, statements of RWI are reported orally
nd in writing to all members of the writing panel at every
eeting and conference call and are updated as changesccur.
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elatively small number of experts engaged in clinical care
nd research in this area, identifying experts without RWI
n this disease area was a challenge. To mitigate this concern
nd reduce the risk of bias, extensive peer review was
ompleted in addition to review and approval by the AHA’s
cientific Advisory Coordinating Committee (SACC) and
he ACCF’s Board of Trustees. SACC members only partic-
pate in the review and approval process if they have no relevant
WI themselves. To provide complete transparency, the RWI
nformation for writing committee members and peer review-
rs are published in the appendixes of the document.
Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on
Expert Consensus Documents
. Executive Summary
ulmonary hypertension (PH) is a complex, multidisci-
linary disorder. Recent advances have led to increased
ecognition and new therapies. While some data exist to
orm treatment guidelines, other areas have been inade-
uately explored.
.1. Pathology and Pathogenesis
ulmonary arterial hypertension (PAH) is a syndrome
esulting from restricted flow through the pulmonary arte-
ial circulation resulting in increased pulmonary vascular
esistance and ultimately in right heart failure. Multiple
athogenic pathways have been implicated in the develop-
ent of PAH, including those at the molecular and genetic
evels and in the smooth muscle and endothelial cells and
dventitia. The imbalance in the vasoconstrictor/vasodilator
ilieu has served as the basis for current medical therapies,
lthough increasingly it is recognized that PAH also in-
olves an imbalance of proliferation and apoptosis (favoring
he former).
.2. Classification and Epidemiology
hile previously considered a rare disease, the most recent
vidence from a French registry suggests that the prevalence
f PAH is about 15 per million (1). Idiopathic pulmonary
rterial hypertension (IPAH) is more prevalent in women
nd was the most common type of PAH in the French
egistry. Familial PAH often results from a mutation in the
one morphogenic protein receptor-2 (BMPR2) and is
nherited as an autosomal dominant disease with incomplete
enetrance and genetic anticipation. PAH is also associated
ith congenital heart disease (CHD), connective tissue
iseases, drugs and toxins, human immunodeficiency virus
HIV), portal hypertension, hemoglobinopathies, and my-
loproliferative disorders. Primary PH formerly encom-
assed idiopathic, familial, and anorexigen induced PAH.
hese groups together comprise World Health Organiza-ion (WHO) Group I PAH. Other WHO categories enclude Group II, PH with left heart disease, Group III, PH
ssociated with lung diseases and/or hypoxemia, Group IV,
H due to chronic thrombotic and/or embolic disease, and
roup V, miscellaneous causes of PH (Table 1).
.3. Natural History and Survival
he prognosis of PAH is poor, with an approximately 15%
ortality within 1 year on modern therapy (2). Predictors of
poor prognosis include: advanced functional class, poor
xercise capacity as measured by 6-minute walk (6MW) test
r cardiopulmonary exercise test, high right atrial (RA)
ressure, significant right ventricular (RV) dysfunction,
vidence of RV failure, low cardiac index, elevated brain
atriuretic peptide (BNP), and underlying diagnosis of
cleroderma spectrum of diseases.
.4. Screening and Diagnostic Assessment
atients at sufficient risk for the development of PAH to
arrant periodic screening include those with a known
MPR2 mutation, scleroderma spectrum of diseases, and
ortal hypertension who are undergoing evaluation for liver
ransplantation. The most appropriate study to obtain in
atients suspected of having PH based on history, physical
able 1. Revised WHO Classification of PH
. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH):
1.3.1. Connective tissue disorder
1.3.2. Congenital systemic-to-pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
1.3.6. Other (thyroid disorders, glycogen storage disease,
Gaucher’s disease, hereditary hemorrhagic telangiectasia,
hemoglobinopathies, chronic myeloproliferative disorders,
splenectomy)
1.4. Associated with significant venous or capillary involvement
1.4.1. Pulmonary veno-occlusive disease (PVOD)
1.4.2. Pulmonary capillary hemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn
. Pulmonary hypertension with left heart disease
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
. Pulmonary hypertension associated with lung diseases and/or hypoxemia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
. Pulmonary hypertension due to chronic thrombotic and/or embolic
disease (CTEPH)
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Nonthrombotic pulmonary embolism (tumor, parasites,
foreign material)
. Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of
pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)
eprinted from Simonneau et al. (32).xamination, chest x-ray (CXR), and electrocardiogram
(
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tiologies, such as thromboembolic disease, is appropriate in
ll patients suspected of having PAH. The diagnosis of
AH requires confirmation with a complete right heart
atheterization (RHC). The current hemodynamic defini-
ion of PAH is a mean pulmonary artery pressure (mPAP)
reater than 25 mm Hg; a pulmonary capillary wedge
ressure (PCWP), left atrial pressure, or left ventricular
nd-diastolic pressure (LVEDP) less than or equal to 15
m Hg; and a pulmonary vascular resistance (PVR) greater
han 3 Wood units (3). Acute vasodilator testing, which
nvolves the administration of pharmacologic agents to test
he presence of pulmonary vasoreactivity, has prognositic
alue and should be performed in all IPAH patients who
ight be considered potential candidates for long-term
alcium-channel blocker therapy. Those with overt right
eart failure or hemodynamic instability should not undergo
cute vasodilator testing. The definition of an acute re-
ponder is a reduction in mPAP of at least 10 mm Hg to an
bsolute mPAP of less than 40 mm Hg without a decrease
n cardiac output. Vasodilator testing should be performed
y centers with experience in the administration of these
gents and the interpretation of the results.
.5. Evidenced-Based Treatment Algorithm
oals of treatment include improvement in the patient’s
ymptoms, quality of life, and survival. Objective assess-
ents to measure treatment response include improvement
n exercise capacity (6MW test, cardiopulmonary exercise
est, treadmill test), hemodynamics, and survival. General
easures that should be addressed include diet, exercise,
ppropriate vaccinations, and avoidance of pregnancy. War-
arin anticoagulation is recommended in all patients with
PAH based on 1 prospective and 2 retrospective observa-
ional, uncontrolled trials. Diuretics are used for symptom-
tic management of RV volume overload. Oxygen is rec-
mmended to maintain oxygen saturation greater than 90%.
alcium channel blockers are indicated only for patients
ho have a positive acute vasodilator response as described
n the preceding text. Patients treated with calcium channel
lockers should be followed closely for both the safety and
he efficacy of this therapy. Continuous intravenous epopro-
tenol improves exercise capacity, hemodynamics, and sur-
ival in IPAH and is the preferred treatment option for the
ost critically ill patients. Although expensive and cumber-
ome to administer, epoprostenol is the only therapy for
AH that has been shown to prolong survival. Treprostinil,
prostanoid, may be delivered via either continuous intra-
enous or subcutaneous infusion. Iloprost is a prostanoid
elivered by an adaptive aerosolized device 6 times daily.
he delivery system and side effects of the prostanoids
hould be carefully considered when assessing patients for
rostanoid therapy. The endothelin receptor antagonists are
ral therapies that improve exercise capacity in PAH. Liver
unction tests must be monitored indefinitely on a monthly
asis. Phosphodiesterase (PDE)-5 inhibitors also improve uxercise capacity and hemodynamics in PAH. In general,
atients with poor prognostic indexes should be initiated on
arenteral therapy, while patients with class II or early III
ymptoms commonly commence therapy with either endo-
helin receptor antagonists or PDE-5 inhibitors. Given the
ultiple mechanisms of action, there is scientific rationale
or the use of combination therapy for PAH, which is an
rea of active investigation. Initial results are encouraging
nd more combination therapy trials are underway. Lung
ransplantation is an option for selected patients who
rogress despite optimal medical management.
.6. Reassessing Patients Over Time:
ow to Follow Patients on Treatment
ue to the complex nature of the disease and its treatments,
AH patients must be closely followed. In general, office
isits should be more frequent for patients with advanced
ymptoms, right heart failure, and advanced hemodynamics
nd those on parenteral or combination therapy. Such
atients generally should be seen every 3 months (or more
requently). Less ill patients on oral therapy generally should
e seen every 3 to 6 months. Most experts obtain an
ssessment of functional class and exercise capacity, such as
6MW or graded treadmill test, with each office visit.
urse clinicians experienced in the care of PAH patients
hould be an integral part of chronic outpatient management.
.7. Non-Pulmonary Arterial Hypertension
ulmonary Hypertension Populations
ost cardiologists and pulmonologists will see PH associ-
ted with elevated left heart filling pressures much more
requently than PAH. Any disorder that elevates left heart
lling pressures, including systolic dysfunction, diastolic
ysfunction, and valvular heart disease, can result in elevated
ulmonary artery pressures. Treatment should be directed at
he underlying left heart disease. In rare instances, PAH-
pecific therapy may be considered if the underlying cause
as been optimally treated, the PCWP is normal or mini-
ally elevated, the transpulmonary gradient and pulmonary
ascular resistance are significantly elevated, and the pa-
ient’s symptoms suggest that PAH-specific therapy may
ield clinical benefit. This subset of patients may be de-
cribed as those with “disproportionate” PH (greater than
xpected on the basis of their elevated left heart pressure or
ung disease). Experts caution against widespread treatment
or non-PAH PH until clinical trial data indicate whether
uch patients benefit from them. The potential adverse
ffects of PAH-specific therapies in such patients include
orsening fluid retention, pulmonary edema, and ventila-
ion perfusion mismatch.
.8. Pulmonary Arterial Hypertension in
ongenital Heart Disease
he incidence of CHD is approximately 8 per 1,000 live
irths (4), and approximately 30% of children who do not
ndergo surgical repair will develop pulmonary vascular
d
c
I
b
1
P
b
s
i
o
a
a
2
T
d
b
a
l
p
b
r
c
A
H
t
t
e
r
r
c
c
2
i
t
u
f
C
m
a
r
e
p
t
t
a
e
d
o
e
m
c
n
i
m
s
w
3
P
t
i
(
v
p
a
n
P
t
p
i
b
k
a
(
n
a
K
i
i
c
a
3
P
p
t
c
i
e
a
m
m
h
f
o
m
t
3
R
a
d
P
1578 McLaughlin et al. JACC Vol. 53, No. 17, 2009
Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619isease. Patients with PAH related to CHD who are not
andidates for surgical correction are treated similar to
PAH patients. The natural history of such patients tends to
e better than those with other types of PAH.
.9. Pediatric Pulmonary Arterial Hypertension
ersistent PH of the newborn is a syndrome characterized
y increased pulmonary vascular resistance, right to left
hunting, and severe hypoxemia. Treatment options include
nhaled nitric oxide (iNO) and extracorporeal membrane
xygenation. Pediatric IPAH is treated similar to that in
dults. A higher percentage of children are acute responders
nd candidates for calcium channel blockers.
. Introduction
he field of PH has evolved substantially over the past
ecade. While there are some data from which evidence
ased guidelines for PAH have been generated, other
spects of the assessment and management of PH have been
argely unexplored.
The writing committee consisted of acknowledged ex-
erts in the field of PH. In addition to members designated
y the ACCF and AHA, the Writing Committee included
epresentation from the American College of Chest Physi-
ians (ACCP); the American College of Rheumatology; the
merican Thoracic Society, Inc. (ATS); and the Pulmonary
ypertension Association (PHA). This diverse representa-
ion reflects the multidisciplinary nature of PH. Represen-
ation by an outside organization does not necessarily imply
ndorsement. This document was reviewed by 4 official
epresentatives from the ACCF and AHA; organizational
eview by the ACCP, ATS, and PHA; as well as by 13
ontent reviewers. This document was approved for publi-
ation by the governing bodies of the ACCF in November
008 and AHA in February 2009. In addition, the govern-
ng boards of the ACCP, ATS, and PHA formally endorsed
his document. This document will be considered current
ntil the Task Force on ECDs revises it or withdraws it
rom publication.
This statement is the first ACCF/AHA Clinical Expert
onsensus Document on PH. At its first meeting, each
ember of this ACCF/AHA Writing Committee indicated
ny relationships with industry, and these relationships were
eiterated at each subsequent meeting and on each confer-
nce call. Relevant conflicts of the writing committee and
eer reviewers are reported in Appendixes 1 and 2, respec-
ively. At the first meeting the writing committee discussed
he topics to be covered in the document and assigned lead
uthors for each section. The entire writing group reviewed
ach section and discussed important issues for further
rafts. The committee met again to come to a consensus on
utstanding issues, and further meetings and teleconfer-
nces occurred between the chairman and writing group
embers who were not present at the meetings to ensure (onsensus on important points. In instances where there was
ot consensus amongst the writing group, a majority opin-
on and a minority opinion is presented. Each writing group
ember has read and approved the entire document. Out-
ide peer review was also undertaken before the document
as finalized.
. Pathology and Pathogenesis
AH is a syndrome resulting from restricted flow through
he pulmonary arterial circulation, which leads to patholog-
cal increases in PVR and ultimately to right heart failure
5). The predominant cause of increased PVR is loss of
ascular luminal cross section due to vascular remodeling
roduced by excessive cell proliferation and reduced rates of
poptosis, although excessive vasoconstriction plays a sig-
ificant role in approximately 20% of patients (6,7).
Improved understanding of the disease pathways in
AH, even if a single primary cause remains elusive, has led
o therapeutic strategies, including the administration of
rostanoids, the antagonism of endothelin receptors, and
nhibition of PDE-5. Future therapeutic options identified
y basic studies include inhibiting pyruvate dehydrogenase
inase (PDK), the serotonin transporter (5-HTT), the
ntiapoptotic protein survivin, several transcription factors
notably hypoxia inducible factor-1 alpha [HIF-1 alpha]
uclear factor activating T lymphocytes [NFAT]), and
ugmenting voltage-gated potassium channel channels (e.g.,
v1.5). Additional therapies in early clinical development
nclude vasoactive intestinal peptide and tyrosine kinase
nhibitors. Administration of angiogenic factors and stem
ells and agents targeting mitochondrial dysfunction may
lso have therapeutic promise.
.1. Histology
AH is a panvasculopathy predominantly affecting small
ulmonary arteries (also called “resistance arteries” because
hey regulate regional blood flow in the lung) (8). PAH is
haracterized by a variety of arterial abnormalities, including
ntimal hyperplasia, medial hypertrophy, adventitial prolif-
ration, thrombosis in situ, varying degrees of inflammation,
nd plexiform arteriopathy. An individual patient may
anifest all of these lesions, and the distribution of lesions
ay be diffuse or focal. Our understanding of the natural
istory of the evolution of vascular lesions in PAH, except
or patients with CHD, is limited because biopsies are rarely
btained in adult patients. However, it is believed that
edial hypertrophy is an earlier and more reversible lesion
han intimal fibrosis or plexogenic arteriopathy.
.2. The Right Ventricle
V function is a major determinant of functional capacity
nd prognosis in PAH (5). While RV hypertrophy and
ilatation are initiated by increased afterload (i.e., elevated
VR), the adequacy of the RV’s compensatory responsepreservation of stroke volume) is quite variable amongst
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensionndividuals. It remains unclear why some RVs compensate
hile others decompensate, manifest as thinning and dila-
ation of the wall, and reduce the RV ejection fraction. The
eonatal RV is much more tolerant of increased PVR,
artially explaining the better survival in children with PAH
ssociated with CHD. RV function could potentially be
mproved by effective therapies to regress pulmonary vascu-
ar obstruction or by directly improving RV contractile
unction.
.3. Molecular Abnormalities in Pulmonary
rterial Hypertension
he pathobiological mechanisms of PAH have recently
een reviewed (9). The PAH “phenotype” is characterized
y endothelial dysfunction, a decreased ratio of apoptosis/
roliferation in pulmonary artery smooth muscle cells
PASMCs), and a thickened, disordered adventitia in which
here is excessive activation of adventitial metalloproteases.
ike cancer and atherosclerosis, PAH does not have a single
ause: a “multi-hit model” is more likely.
.4. Genetics of Pulmonary Arterial Hypertension
AH is inherited in less than 10% of cases (1,10). Muta-
ions in 2 genes in the transforming growth factor beta
eceptor pathway, BMPR2, and activin-like kinase 1 have
een implicated in the pathogenesis of familial PAH.
MPR2 modulates vascular cell growth by activating the
ntracellular pathways of SMAD and LIM kinase (11–13)
any different BMPR2 mutations occur in familial PAH.
hese mutations, which lead to loss of function in the
MAD signaling pathway, are prevalent in familial PAH
prevalence 75%) (11,12). Activin-like kinase 1 muta-
ions, detected in a group of patients with hereditary
emorrhagic telangiectasia and PAH (13), are also thought
o result in growth-promoting alterations of SMAD-
ependent signaling. Overexpression of a dominant nega-
ive form of BMPR2 in PASMC leads to PAH and Kv1.5
ownregulation in transgenic mice (14,15).
.5. Abnormalities in the Blood and Endothelium in
ulmonary Arterial Hypertension
n the vascular lumen, PAH is characterized by platelets
hat are depleted of serotonin and elevation of plasma
erotonin (16). Endothelial dysfunction is common in
AH. The PAH endothelium is characterized by increased
roduction of vasoconstrictor/mitogenic compounds, such
s endothelin and thromboxane, and deficient production of
asodilators, such as prostacyclin (17–19). Elevated levels of
brinopeptide A and plasminogen activator inhibitor-1 and
educed levels of tissue plasminogen activator contribute to
he procoagulant state. Endothelial injury may also expose
he underlying smooth muscle cells to circulating mitogens
nd growth factors that stimulate cell proliferation.
.6. Prostacyclin and Thromboxane A2
he prostanoids prostacyclin and thromboxane A2 are
ajor arachidonic acid metabolites. Prostacyclin is a potent oasodilator, inhibits platelet activation, and has antiprolif-
rative properties, whereas thromboxane A2 is a potent
asoconstrictor and promotes proliferation platelet activa-
ion. In PAH, the balance between these 2 molecules is
hifted toward thromboxane A2 (17), favoring thrombosis,
roliferation, and vasoconstriction. Additionally, prostacy-
lin synthase is decreased in the small- and medium-sized
ulmonary arteries in PAH (20).
.7. Endothelin-1
ndothelin-1 (ET-1) is a potent vasoconstrictor and stim-
lates PASMC proliferation. Plasma levels of ET-1 are
ncreased in PAH and correlate with severity of PAH and
rognosis (21). Moreover, clearance of ET-1 in the pulmo-
ary vasculature is reduced in PAH (19).
.8. Nitric Oxide
itric oxide (NO) is a vasodilator and inhibitor of platelet
ctivation and vascular smooth-muscle cell proliferation.
O is produced by 3 isoforms of nitric oxide synthases
NOS). Decreased endothelial NOS (NOS3) has been
bserved in PAH patients (18). Once formed, the effects of
O are largely mediated by cyclic guanosine monophos-
hate (cGMP) which is rapidly inactivated by PDE, espe-
ially the PDE-5 isoenzymes. eNOS knockout mice display
H and even more profound systemic hypertension (22).
DE-5 is present in large amounts in the lung, giving
ationale for the use of PDE-5 inhibitors in PAH.
.9. Additional Vasoactive Substances
erotonin (5-hydroxytryptamine) is a vasoconstrictor and
romotes PASMC hypertrophy and hyperplasia. Allelic
ariation in serotonin transporter (5-HTT) and the
-hydroxytryptamine 2B receptor (5-HT2B), have been
escribed in platelets and lung tissue from patients with
AH (23). Transgenic mice overexpressing the serotonin
ransporter have PAH and decreased Kv1.5 expression (14).
espite these observations, the level of serotonin alone is
ot likely a determinant of PAH, since serotonin-reuptake
nhibitors are in widespread clinical use but are not associ-
ted with an increased incidence of PAH and may, in fact,
e a potential PAH therapy (24). Vasoactive intestinal
eptide (VIP) is a member of the glucagon-growth
ormone-releasing superfamily and has a pharmacologic
rofile similar to prostacyclins. Serum and lung tissue VIP
evels are decreased in PAH patients, and exogenous VIP may
ecrease pulmonary artery pressure (PAP) and PVR, inhibit
latelet activation, and reduce PASMC proliferation (25).
.10. Inflammation
utoantibodies, proinflammatory cytokines, and inflamma-
ory infiltrates have been observed in some cases of PAH,
uggesting that inflammation may contribute to the devel-
pment of some forms of PAH (26).
3
P
I
f
m
f
c
e
a
m
s
T
i
p
i
p
m
f
e
o
A
P
r
l
m
(
m
b
o
f
p
t
t
4
P
(
T
4
I
a
e
b
6
a
o
7
4
H
a
9
i
i
r
f
B
(
c
g
i
d
4
W
P
i
s
a
d
t
l
v
a
p
d
4
W
A
i
s
R
t
v
P
S
s
t
a
s
o
t
4
W
P
t
t
s
T
o
1580 McLaughlin et al. JACC Vol. 53, No. 17, 2009
Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619.11. Pulmonary Artery Smooth Muscle Cells in
ulmonary Arterial Hypertension
n PAH, PASMCs have a collection of abnormalities that
avor a decreased apoptosis/proliferation ratio. These abnor-
alities include inappropriate activation of transcription
actors (HIF-1 alpha and NFAT), decreased expression of
ertain K channels (e.g., Kv1.5 and Kv2.1), and de novo
xpression of the antiapoptotic protein survivin. Several
bnormalities are observed in human PAH and in rodent
odels of PAH (notably loss of Kv1.5, activation of
urvivin, and nuclear translocation of HIF-1 alpha) (27,28).
he PASMCs in PAH also display excessive proliferation
n response to transforming growth factor beta, and this
ropensity to accumulate unwanted cells is exacerbated by
mpaired smooth muscle cell apoptosis. The impaired apo-
tosis appears to be multifactorial, related to abnormal
itochondrial hyperpolarization, activation of transcription
actors (such as HIF-1 alpha and NFAT), and de novo
xpression of the antiapoptotic protein survivin (27). This
ccurs in both the PASMCs and endothelial cells (29).
nother factor that promotes calcium overload and
ASMC proliferation is increased expression of transient
eceptor potential channels, which promotes calcium over-
oad (30).
In PAH the adventitia is fragmented, permitting cell
igration and creating mitogenic peptides, such as tenascin
31). It is conceivable that inhibition of metalloproteases
ay have therapeutic potential in PAH.
While great strides have been made in understanding the
asic mechanisms of the pathobiology and the pathogenesis
f PAH over the past 2 decades, our understanding is far
rom complete. Ongoing investigation into many novel
athways will potentially lead to more therapeutic options in
he decades to come. Figure 1 (31a) summarizes many of
he relevant cellular pathways in the pathogenesis of PAH.
. Classification and Epidemiology of
ulmonary Arterial Hypertension
WHO Group I)
he current classification of PH is depicted in Table 1 (32).
.1. Idiopathic Pulmonary Arterial Hypertension
PAH is a rare disease, with a female/male ratio of 1.7:1 and
mean age at diagnosis of 37 years (10). Most recent
pidemiologic data suggest that the prevalence of PAH may
e up to 15 per million, with a prevalence of IPAH of about
per million (1). Interestingly, recent studies suggest the
ge range of affected individuals may be increasing, as cases
f IPAH have been reported in many patients greater than
0 years old (33).
.2. Familial Pulmonary Arterial Hypertension
ereditary transmission of PAH has been reported in
pproximately 6% to 10% of patients with PAH; in 50% to t0% of these individuals, mutations in BMPR2 have been
dentified (34,35). Mutations in BMPR2 have been found
n up to 25% of patients with IPAH (36), in 15% of PAH
elated to fenfluramine use, and rarely in patients with other
orms of associated PAH (37,38). The mutations in
MPR2 in familial pulmonary arterial hypertension
FPAH) are characterized by genetic anticipation and in-
omplete penetrance. The phenotype is not expressed in all
enerations, but when expressed, occurs at an earlier age and
s associated with more severe and rapidly progressive
isease (39,40).
.3. Pulmonary Arterial Hypertension Associated
ith Congenital Heart Disease
AH is a well-recognized complication of uncorrected
ncreased pulmonary blood flow associated with CHD and
ystemic-to-pulmonary shunts. The development of PAH
nd subsequent reversal of shunt flow (Eisenmenger syn-
rome) occurs more frequently when blood flow is ex-
remely high and the shunt exposes the pulmonary vascu-
ature to systemic level pressures, such as occurs with a
entricular septal defect, patent ductus arteriosus, or truncus
rteriosus. However, PAH may also occur with low
ressure-high flow abnormalities, such as with atrial septal
efects.
.4. Pulmonary Arterial Hypertension Associated
ith Connective Tissue Diseases
primary pulmonary arteriopathy occurs most commonly
n patients with the limited cutaneous form of systemic
clerosis, formerly referred to as the CREST (calcinosis,
aynaud’s, esophageal dysfunction, sclerodactaly, telangec-
asias) variant. Although at autopsy, 65% to 80% of indi-
iduals have histopathological changes consistent with
AH, less than 10% develop clinically apparent disease (41).
urveillance echocardiography suggests that there is a sub-
tantial prevalence of mild to moderate PH in connective
issue disease patients (41,42). However, the management
nd natural history of such patients has not been well
tudied. Histology consistent with PAH has also been
bserved in systemic lupus erythematosus, mixed connective
issue disease, and rheumatoid arthritis.
.5. Pulmonary Arterial Hypertension Associated
ith Human Immunodeficiency Virus Infection
opulation studies of individuals infected with HIV suggest
hat the incidence of PAH is approximately 0.5%, or 6 to 12
imes that of the general population, and has not declined
ignificantly with aggressive antiretroviral therapy (43–45).
he occurrence of PAH is independent of the CD4 count
r previous opportunistic infections, but appears related to
he duration of HIV infection (46). Although PAH occurs
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensionith greater frequency in individuals who have used intra-
enous drugs, no clear etiological link has been established
ith foreign body emboli or the portal hypertension fre-
uently observed in these same individuals because of
oncomitant infection with hepatitis B or C. Because HIV
oes not directly infect vascular endothelial cells or smooth
uscle cells, the mechanism of PAH in HIV infection
emains unclear. Routine screening for PAH in HIV is not
ecommended due to the relatively low disease prevalence in
igure 1. Relevant Pathways in the Pathogenesis of Pulmonary Ar
chematic depicting the potential “hits” involved in the development of PAH. A rise
zation, which opens VDCCs; upregulated TRPC channels that participate in forming
e.g., serotonin, endothelin, or leukotriene receptors] ➂ and their downstream signa
nhibits the BMP-signaling pathway that leads to antiproliferative and proapoptotic ef
MP-RI downregulation ➃ and inhibition of Kv channel function and expression ➀ att
nd release ➄ from PASMCs enhance 5-HT production and downregulate BMP-RIA in
xide and prostacyclin synthesis ➅ in PAECs would attenuate the endothelium-derive
ASMC proliferation. Increased activity and expression of the 5-HTT ➆ would serve a
ariety of splicing factors, transcription factors, protein kinases, extracellular metallo
otypical transition of normal cells to contractive or hypertrophied cells and to maint
-HT indicates 5-hydroxytryptamine; 5-HTT, 5-HT transporter; 5-HTR, 5-hydroxytryptop
rotein; BMP-RI, BMP type I receptor; BMP-RII, BMP type II receptor; BMPR-IA, BMP r
rol; Em, membrane potential; ET-1, endothelin-1; ET-R, endothelin receptor; GPCR, G
ated potassium channel; MAPK, mitogen-activated protein kinase; NO/PGI2, nitric o
ypertension; PASMC, pulmonary artery smooth muscle; PDGF, platelet-derived grow
LC, PLC gamma; PKC, protein kinase C; ROC, receptor-operated calcium channel;
tore-operated channel; SR, sarcoplasmic reticulum; TIE2, tyrosine-protein kinase re
hannel. Reprinted from Yuan and Rubin (31a).IV patients. p.6. Pulmonary Arterial Hypertension Associated
ith Portal Hypertension
n a large autopsy series, histological changes consistent
ith PAH occurred in 0.73% of individuals with cirrhosis,
times the prevalence in all autopsies (47). Hemodynamic
tudies have estimated the prevalence of PAH in these
ndividuals at 2% to 6%; however, the prevalence may be
igher in patients referred for liver transplantation (48). The
isk of developing PAH increases with the duration of
Hypertension
]cyt in PASMCs (due to increased Kv channel activity ➀ and membrane depolar-
r- and store-operated Ca2 channels ➁; and upregulated membrane receptors
scades) causes pulmonary vasoconstriction, stimulates PASMC proliferation, and
n PASMCs. Dysfunction of BMP signaling due to BMP-RII mutation and BMP-RII/
PASMC apoptosis and promote PASMC proliferation. Increased Ang-1 synthesis
s and further enhance PASMC contraction and proliferation, whereas inhibited nitric
xing effect on pulmonary arteries and promote sustained vasoconstriction and
dditional pathway to stimulate PASMC growth via the MAPK pathway. In addition, a
nases, and circulating growth factors would serve as the “hits” to mediate the phe-
progression of PAH.
ng-1, angiopoietin; AVD, apoptotic volume decrease; BMP, bone morphogenetic
r IA; Ca2, calcium ion; Co-Smad, common smad; cyt, cytosine; DAG, diacylglyc-
in-coupled receptor; IP3, inositol 1,4,5-trisphosphate; K, potassium; Kv, voltage-
rostacyclin; PAEC, pulmonary arterial endothelial cell; PAH, pulmonary arterial
or; PIP2, phosphatidylinositol biphosphate; PLC, phospholipase C; PLC, PLC-beta;
d, receptor-activated smad signaling pathway; RTK, receptor tyrosine kinase; SOC,
; TRPC, transient receptor potential channel; and VDCC, voltage-dependent calciumterial
in [Ca2
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619nclear, but cirrhosis without the presence of portal hyper-
ension appears insufficient for the development of PAH.
ortal hypertension patients may also develop PH related to
igh flow states and left ventricular (LV) diastolic dysfunc-
ion, which are important to distinguish from PAH.
.7. Pulmonary Arterial Hypertension Associated
ith Drugs and Toxins
ssociation between anorexigens (appetite suppressant
rugs that increase serotonin release and block serotonin
euptake) and PAH was initially observed in the 1960s
hen an epidemic of IPAH (then termed PPH) was noted
n Europe following the introduction of aminorex fumarate
49). Upon withdrawal of this medication, the incidence of
AH decreased to background; however, structurally related
ompounds, such as fenfluramine and dexfenfluramine,
ere subsequently developed in the 1980s. Exposure to
hese agents for as little as 3 months also has been associated
ith an increased incidence of IPAH (50). Epidemiologic
tudies have also linked the development of PAH to
apeseed oil (51), L-tryptophan (52), and illicit drugs such
s methamphetamine and cocaine (53,54).
.8. Pulmonary Arterial Hypertension Associated
ith Hemoglobinopathies
H is increasingly recognized in patients with sickle cell
isease, with a prevalence reported as high as 30% in
chocardiography-based studies (55,56). A more recent
eport suggests that the proportion of patients with sickle
ell disease who have PAH is much lower, less than 10%
57). It also highlights other factors that may contribute to
H in sickle cell disease patients including thromboembolic
isease, restrictive lung disease, and left heart disease.
hether the PH is the cause of the increased mortality or
s a surrogate marker remains unclear; however, the 2-year
ortality rate in these patients is approximately 50%
55,56). The pathobiology of PH in sickle cell disease is
ikely multifactorial: sickle cell related pulmonary vasculopa-
hy, asplenia, pulmonary parenchymal and vascular injury
rom acute chest syndrome, and systemic loss of bioavailable
O by hemoglobin released during hemolysis and increased
xidant burden (58). Plasma levels of endothelin-1 are
levated in patients with sickle cell disease (59). Despite the
elatively mild nature of the PH in many of these patients,
he histopathology is often quite similar to PAH, including
lexiform lesions. Hemodynamic parameters in PH associ-
ted with sickle cell disease are often different from those in
ther forms of PAH. PAP and PVR are often lower than
hat observed in IPAH, yet patients with sickle cell disease
nd PH are often very symptomatic. In contrast to patients
ith other forms of PAH, who by definition have normal
V systolic and diastolic function, sickle cell disease-PH
atients often have elevated left heart filling pressures
uggesting impaired LV diastolic function. They also have
ecreased hemoglobin and a high cardiac output but haveimited systemic oxygen transport. Other anemias, including womozygous beta-thalassemia and hereditary spherocytosis
ave also been associated with the development of PH
60,61).
.9. Pulmonary Arterial Hypertension Associated
ith Other Etiologies
H clinically and histologically indistinguishable from
PAH has been observed in approximately 15% of individ-
als with hereditary hemorrhagic telangiectasia, an autoso-
al dominant vascular dysplasia (13,62). There is also an
ssociation between thrombocytosis, chronic myelodysplas-
ic syndrome, and the development of PAH (63). Lastly, a
igh incidence of asplenia and thyroid disease have been
eported in patients with PAH (64,65).
.10. Pulmonary Arterial Hypertension Associated
ith Pulmonary Venous or Capillary Abnormalities
n rare instances, the typical histological findings of PAH
re associated with an occlusive venopathy (pulmonary
eno-occlusive disease) or a microvasculopathy (pulmonary
apillary hemangiomatosis). In addition to the histology of
AH, these entities also exhibit the findings of pulmonary
enous hypertension, including pulmonary hemosiderosis,
nterstitial edema, and lymphatic dilation (66). Although
he clinical presentation is usually indistinguishable from
AH, rapid development of pulmonary edema after admin-
stration of vasodilators such as epoprostenol has been
eported in both entities (67,68) and is often a clue to the
ppropriate diagnosis.
. Natural History and Survival
he prognosis of PAH and variables influencing the prog-
osis have recently been reviewed (69). The natural history
f IPAH has been well characterized. The National Insti-
utes of Health (NIH) Registry followed 194 patients with
PAH enrolled at 32 clinical centers from 1981 to 1985
70). The estimated median survival was 2.8 years, with 1-,
-, and 5-year survival rates of 68%, 48%, and 34%,
espectively. Studies from Japan, India, and Mexico have
uggested similar results, with a median survival in the range
f 2 to 3 years.
Prognosis is also influenced by underlying etiology (Fig-
re 2). The prognosis in patients with PAH associated with
he scleroderma spectrum of diseases appears to be worse
han for IPAH, and the untreated 2-year survival rate may
e as low as 40% (71). Even with epoprostenol therapy,
atients with PAH related to the scleroderma spectrum of
iseases have a less favorable outcome (72), although recent
ata suggest that in the era of expanding PAH therapy,
rognosis may be improving (73). Data from 2 studies
prospective and retrospective) suggest that patients with
IV-associated PAH appear to have similar survival as
hose with IPAH (43,74), and deaths in this setting are
ost commonly related to PAH. It is clear that patients
ith CHD have a better prognosis than those with IPAH,
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensionlthough it is uncertain whether this reflects the relative
outh of these patients, their better adapted right ventricles,
r the potential advantages of a residual shunt. In a study
valuating 100 adults with severe PAH, 37 of whom had
isenmenger syndrome and 6 of whom had previously
epaired congenital heart defects, actuarial survival of non-
ransplanted patients was 97%, 89%, and 77% at 1, 2, and 3
ears, respectively, compared with 77%, 69%, and 35% at 1,
, and 3 years, respectively, for patients with IPAH (75). In
cohort of epoprostenol-treated PAH patients, survival was
reater for those with CHD than for IPAH (72).
.1. Medical Therapy for Pulmonary Arterial
ypertension: Impact Upon Survival
he positive impact of epoprostenol on survival in IPAH
as been well described in 1 randomized controlled trial and
single center, observational, uncontrolled trials (76–78).
ong-term epoprostenol therapy appears to improve hemo-
ynamics and quality of life in patients with PAH and
HD who fail conventional therapy (79), and improvement
as been demonstrated in the scleroderma spectrum of
iseases population (80), but trials large enough to ade-
uately assess survival benefit are not available.
Long-term observational studies with first line bosentan
nd treprostinil have also suggested an improved survival in
AH, although controlled clinical trial data are not available
81,82). Calcium channel blockers may favorably influence
urvival in the small proportion of patients with IPAH who
emonstrate a significant vasodilator response at RHC
83,84). Anticoagulation therapy has been associated with
mproved survival in IPAH (83) as well as in diet drug-
nduced PAH (85) in open label, uncontrolled series.
owever, a large, prospective randomized trial with the
pecific purpose of looking at this end point has not been
igure 2. Mean Survival of Patients With PAH Based on Etiology
HD indicates congenital heart disease; CTD, connective tissue disease; HIV, huma
PAH, idiopathic pulmonary arterial hypertension; and Portopulm, portopulmonary hyponducted. Recent registry data indicate an 85% survival pate at 1 year for patients with PAH observed at a single
enter from 1982 to 2006 (2).
.2. Factors Impacting Survival and
acilitating Assessment of Prognosis
mportant prognostic factors have recently been reviewed
69) and will be briefly summarized.
.3. Functional Class
he NIH cohort study showed that among 194 patients
ho received a diagnosis of IPAH between 1981 and 1985,
he risk of death was higher among patients in New York
eart Association (NYHA) functional class III or IV than
mong those in NYHA functional class I or II. In the NIH
egistry, the median survival among patients presenting with
YHA functional class I and II symptoms was nearly 6
ears versus 2.5 years for patients with functional class III
ymptoms and just 6 months for patients who presented
ith functional class IV symptoms (70). Other series have
onfirmed the importance of functional class as a prognostic
ariable, even during treatment (77,78). Mortality is higher
n both treated and untreated functional class III but
articularly in functional class IV IPAH patients. Patients
ho improved to functional class I or II status with
poprostenol had a better prognosis than patients who
emained in functional class III or IV (77,78).
.4. Exercise Tolerance
n the pivotal epoprostenol IPAH trial, performance in the
nencouraged 6MW test was found to be an independent
redictor of survival, leading to use of this test as the
rimary end point for many prospective trials (76). Other
tudies have suggested the prognostic value of this test; in
unodeficiency virus related;
ion. Adapted from McLaughlin et al. (69).n immatients on epoprostenol, unencouraged 6MW distance at
b
s
p
f
i
s
1
t
p
h
a
t
b
n
t
d
p
a
5
A
a
r
i
m
1
(
d
i
i
u
v
i
e
s
i
p
e
B
n
e
t
t
a
t
w
m
p
e
i
r
a
c
b
i
I
i
a
(
5
W
P
d
s
d
g
h
d
(
m
s
o
t
o
s
a
e
5
C
s
r
i
f
m
8
t
m
(
b
s
i
o
g
5
B
c
p
b
l
h
c
v
(
p
O
b
1584 McLaughlin et al. JACC Vol. 53, No. 17, 2009
Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619aseline and after 3 months of therapy was associated with
urvival by univariate analysis (78,86).
Maximal oxygen consumption (peak VO2) determined by
rogressive, exercise testing with cycle ergometry has been
ound to be an independent predictor of survival in 1 study
n patients with IPAH (87); Kaplan-Meier analysis in this
tudy revealed that patients with a peak VO2 greater than
0.4 mL/kg/min had significantly better 1-year survival
han patients with lower peak VO2 values. Patients with a
eak systemic blood pressure greater than 120 mm Hg also
ad a better 1-year survival than those patients who did not
chieve this systemic blood pressure. In IPAH patients
reated with epoprostenol, treadmill exercise time has also
een shown to be predictive of survival (77). Cardiopulmo-
ary exercise testing is used less frequently in PAH clinical
rials due to lack of methodologic consistency among
ifferent centers. The Naughton-Balke treadmill test re-
orted in exercise metabolic equivalents is a useful means of
ssessing functional capacity in PAH patients (88).
.5. Hemodynamics
ll large published evaluations implicate hemodynamics as
n important predictor of survival (70,77,78). In the NIH
egistry, 3 hemodynamic variables were associated with an
ncreased risk of death by univariate analysis: increased
PAP (odds ratio [OR]: 1.16; 95% confidence interval:
.05 to 1.28), increased mean right atrial pressure (mRAP)
OR: 1.99; 95% confidence interval: 1.47 to 2.69), and
ecreased cardiac index (CI) (OR: 0.62; 95% confidence
nterval: 0.46 to 0.82). These 3 variables were also predictive
n a multivariate analysis. Data from the NIH registry were
sed to formulate a regression equation in which these 3
ariables were used to estimate survival. Data from Mexico
n the pre-epoprostenol era support the validity of the NIH
quation, and suggest the importance of other predictors
uch as decreased mixed venous oxygen (MVO2) and
ncreased heart rate (89). Interestingly, mPAP was not a
redictor based upon these data, and this is likely due to the
ventual decrease in mPAP as the right ventricle fails.
aseline hemodynamic variables appear to have less prog-
ostic value in patients with IPAH who are treated with
poprostenol (78). Based upon available data, it is agreed
hat mRAP, CI, and mPAP are predictive of survival, with
he understanding that as RV function worsens, mPAP may
ctually decrease. Experienced clinicians use mRAP and CI
ogether with other clinical parameters to prognosticate.
True vasodilator responders have an excellent prognosis,
ith up to a 95% survival at 5 years (83,84). Although the
ain purpose of acute vasodilator testing is to identify
atients that might respond to oral calcium channel block-
rs, the results of vasodilator testing also have prognostic
mplications. The issue of whether degree of vasodilator
esponsiveness has prognostic implications in patients who
re treated with medical therapies other than calcium
hannel blockers is controversial. However, calcium channel
lockers should not be considered as PAH-specific therapy af there is not an acute response to a short acting vasodilator.
n a large series of patients with IPAH receiving long-term
ntravenous epoprostenol, the change in PVR acutely with
denosine was predictive of survival by a univariate analysis
77).
.6. Echocardiography
hile echocardiography has been a pivotal screening test in
AH, studies evaluating the prognostic value of echocar-
iographic parameters have been limited to relatively small
eries. RA and RV enlargement, reduced RV function,
isplacement of the intraventricular septum, tricuspid re-
urgitation (TR), the Tei index, and pericardial effusion
ave been evaluated. The presence of any degree of pericar-
ial effusion has proven a consistent predictor of mortality
90). The Doppler echocardiographic index (“Tei index” or
yocardial performance index), an index of combined RV
ystolic and diastolic function obtained by dividing the sum
f both isovolumetric contraction and relaxation intervals by
he ejection time, appears to be predictive of an adverse
utcome on univariate analysis and by multivariate regres-
ion analysis (91,92). Clinicians often rely on the subjective
ppearance of the RA and RV to make clinical decisions,
ven without formal size measurements.
.7. Magnetic Resonance Imaging
ardiac magnetic resonance (MR) imaging accurately as-
esses size and function of the RV with a high degree of
eproducibility. RV function is an important prognositic
ndicator in PAH and cardiac MR imaging of poor RV
unction, including stroke volume less than or equal to 25
L/m2, RV end-diastolic volume greater than or equal to
4 mL/m2, and LV end-diastolic volume less than or equal
o 40 mL/m2, were found to be independent predictors of
ortality and treatment failure in a study of 64 patients
93). Additionally, pulmonary artery stiffness, as measured
y relative cross-sectional area change was predictive of
urvival in a cohort of 86 PAH patients studied with MR
maging (94). Those with a relative cross-sectional area change
f less than 16% had a greater mortality than those with value
reater than 16%.
.8. Biomarkers
oth atrial natriuretic peptide and BNP have been shown to
orrelate with survival in IPAH and to correlate with other
redictors of survival. BNP and NT-proBNP appear to be
etter independent predictors (95,96). Increased uric acid
evels, which may reflect impaired oxidative metabolism,
ave been shown to be increased with severity of functional
lass and hemodynamics in IPAH, and among the nonin-
asive tests studied, independently correlated with mortality
97). Detectable cardiac troponin T also confers a poor
rognosis, potentially due to the effect of RV ischemia (98).
f the above biomarkers, proBNP levels are increasingly
eing used and appear to correlate with RV enlargement
nd dysfunction.
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uccessful prognostication of survival is crucial in planning
ppropriate therapeutic measures including aggressive med-
cal therapy and transplantation, and should encompass
ultiple variables. The most conclusive data are available for
PAH, and limited data are available for associated forms of
AH. Important prognostic variables are summarized in
able 2 (PAH: Determinants of Prognosis) (99). While this
able is meant to provide guidance, in many instances, the
ame patient may have a high-risk finding, a low-risk
nding, and/or a finding between the 2. This scheme allows
or latitude in the composite assessment of an individual
atient by the experienced physician.
. Screening and Diagnostic and
emodynamic Assessment
.1. Definition of Pulmonary Hypertension
he term PH refers to the presence of abnormally high
ulmonary vascular pressure. PAH is a category of PH
Venice Group 1) (Table 1) (32); the 2 terms are not
ynonymous. The conventional definition of PAH used in
linical studies includes an mPAP of greater than 25 mm Hg
t rest in the setting of a normal pulmonary arterial wedge
ressure of 15 mm Hg or less with a PVR greater than 3
ood units. Patients enrolled in the NIH registry of
rimary PH (now IPAH) in the 1980s had the following
emodynamic characteristics: an mPAP of 60 plus or minus
8 mm Hg, cardiac index of 2.3 plus or minus 0.9
/min/m2, and pulmonary arterial wedge pressure of 8 plus
r minus 4 mm Hg (10). This hemodynamic definition has
ubsequently been applied in enrollment requirements in
irtually every randomized clinical treatment trial along with
dditional criteria including functional classification and
MW test to ensure that a relatively advanced stage of
able 2. PAH*: Determinants of Prognosis
Determinants of Risk Lower Risk (Good Prognosi
linical evidence of RV failure No
rogression of symptoms Gradual
HO class† II, III
MW distance‡ Longer (greater than 400 m)
PET Peak VO2 greater than 10.4 mL/kg/min
chocardiography Minimal RV dysfunction
emodynamics RAP less than 10 mm Hg, CI greater than
NP§ Minimally elevated
eprinted from McLaughlin and McGoon (99). *Most data available pertains to IPAH. Little data is ava
s the functional classification for PAH and is a modification of the New York Heart Association functio
egarding the influence of BNP on prognosis, and many factors including renal function, weight, age
6MW indicates 6-minute walk; BNP, brain natriuretic peptide. CI, cardiac index; CPET, cardio
ressure; RV, right ventricle; and WHO, World Health Organization.isease was studied. l.2. Diagnostic Strategy
he diagnostic strategy for PH depends on the context in
hich it is employed: 1) detection of a substrate in which
he likelihood of a pulmonary vasculopathy may be height-
ned; 2) discovery of the presence of PH; 3) classification of
he type of PH; 4) confirmation of the presence of suspected
H; and 5) determination of an appropriate treatment
ategory. The approach to diagnosis has been previously
utlined (3). The general strategy for assessment is shown in
igure 3.
UBSTRATE RECOGNITION
ertain medical conditions and genetic susceptibilities are
ecognized as predisposing a person to the development of
AH, and were reviewed in Section 4 of this document.
isk factors for PAH and consensus screening guidelines
re displayed in Table 3.
ISCOVERY OF PULMONARY HYPERTENSION
discovery strategy is required for patients who are at risk
f having PH, including those with genetic substrates, risk
actors, or suggestive symptoms or physical examination
ndings. The most common presenting symptoms of PH
nclude dyspnea on exertion, fatigue, chest pain, syncope,
alpitations, and lower extremity edema. Common physical
xamination findings are displayed in Table 4 (100). The
XR and ECG may display markers suggestive of PH that
ear further evaluation (Figure 4).
.3. Echocardiography
f PH is suspected based on the history, risk factor assess-
ent, and physical examination, an echocardiogram is the
ext appropriate study. The Doppler echocardiogram can
imultaneously provide an estimate of RV systolic pressure,
unctional and morphologic cardiac sequelae of PH, and
dentification of possible cardiac causes of PH. Common
chocardiographic findings of PAH are featured in Figure 5.
n the absence of other potential etiologies of PH, such as
Higher Risk (Poor Prognosis)
Yes
Rapid
IV
Shorter (less than 300 m)
Peak VO2 less than 10.4 mL/kg/min
Pericardial effusion, significant RV enlargement/dysfunction,
right atrial enlargement
/min/m2 RAP greater than 20 mm Hg, CI less than 2.0 L/min/m2
Significantly elevated
or other forms of PAH. One should not rely on any single factor to make risk predictions. †WHO class
ss. ‡6MW distance is also influenced by age, gender, and height. §As there is currently limited data
nder may influence BNP, absolute numbers are not given for this variable.
ary exercise testing; peak VO2, average peak oxygen uptake during exercise; RAP, right atrials)
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619ystolic pressure of greater than 40 mm Hg generally
arrants further evaluation in the patient with unexplained
yspnea. Additionally, other echocardiographic findings,
ncluding RA or RV enlargement or intraventricular septal
attening, may also trigger further evaluation. Echocardi-
graphy can also identify coexistent abnormalities that do
ot themselves cause PAH but support a specific diagnosis
Table 5), although many of these findings lack specificity.
The spectral Doppler profile of TR is too weak or
nsufficient to measure the RV to RA pressure gradient in
pproximately 10% to 25% of patients with PH referred for
valuation (101,102). When this problem is encountered,
he spectral TR signal can be enhanced by intravenous bolus
dministration of a small amount of agitated saline contrast,
r with commercially available encapsulated microbubble
ontrast agents that are indicated for use to enhance the LV
ndocardial borders. Very small amounts of these agents are
equired for Doppler enhancement, and encapsulated agents
hould be used with caution in patients with severe pulmo-
Pivotal Tests
Echocardiogram
PFTs
Polysomn
VQ Scan
Functional Test
(6MWT, CPET)
Overnight 
Oximetry
History
Exam
CXR
ECG
HIV
ANA
LFTs
RH Cath
TE
Exercise
Pulmonary A
Chest CT A
Coagulopat
Vasodila
Exercise 
Volume L
ABG
Continge
Other CTD S
Left Hea
igure 3. Diagnostic Approach to PAH
eneral guidelines for the evaluation of pulmonary hypertension. Since the suspicion
is of PAH requires that certain data support a specific diagnosis. In addition, the di
ble possibilities. Pivotal tests are those that are essential to establishing a diagno
xclusion of diagnoses other than IPAH. All pivotal tests are required for a definitive
bstructive pulmonary disease on PFTs), does not preclude that another abnormality
r predominant. Contingent tests are recommended to elucidate or confirm results o
ombination of pivotal and appropriate contingent tests contribute to assessment of
ive diagnosis may require additional specific evaluations not necessarily included in
NA, antinuclear antibody serology; CHD, congenital heart disease; CPET, cardiopulm
XR, chest X-ray; ECG, electrocardiogram; HIV, human immunodeficiency virus scree
unction test; PH, pulmonary hypertension; RA, rheumatoid arthritis; RAE, right atrial
VSP, right ventricular systolic pressure; SLE, systemic lupus erythematosus; TEE, t
erfusion scintigram.ary vascular disease (102a). In these instances, the presence Cf right heart chamber enlargement or septal flattening
uggests elevated right heart pressures.
.4. Exercise Echocardiography
hile hemodynamics are most often measured at rest,
atients usually experience dyspnea with exercise, leading to
n interest in the utility of exercise echocardiography to
etect “exercise-induced PH.” Exercise echocardiography is
hallenging both to perform and interpret and is generally
sed in a research setting. It may not be possible to discern by
chocardiography alone to what extent elevated left heart filling
ressure might contribute to “exercise-induced PH” in an
ndividual patient. The consensus is that no treatment deci-
ions can be made on the basis of exercise-induced PH alone.
.5. Newer Imaging Techniques in the Diagnostic
ssessment of Pulmonary Hypertension
here is considerable interest in the utilization of newer
maging techniques in the assessment of patients with PH.
hy •Sleep Disorder
•Chronic PE
raphy
ram
file
t
th
g
•Index of Suspicion of 
PH
• RVE, RAE, ↑RVSP, RV 
Function
• Left Heart Disease
• VHD, CHD
•Ventilatory Function
•Gas Exchange
sts Contribute to 
Assessment of:
gies
•HIV Infection
•Scleroderma, SLE, RA
•Portopulmonary Htn
•Establish Baseline
•Prognosis
•Confirmation of PH
•Hemodynamic Profile
•Vasodilator Response
may arise in various ways, the sequence of tests may vary. However, the diagno-
is of idiopathic pulmonary arterial hypertension is one of excluding all other reason-
any type of PAH either by identification of criteria of associated disease or
sis and baseline characterization. An abnormality of one assessment (such as
ic thromboembolic disease on VQ scan and pulmonary angiogram) is contributing
ivotal tests, and need only be performed in the appropriate clinical context. The
ifferential diagnoses in the right-hand column. It should be recognized that defini-
eneral guideline. 6MWT indicates 6-minute walk test; ABGs, arterial blood gases;
exercise test; CT, computerized tomography; CTD, connective tissue disease;
tn, hypertension; LFT, liver function test; PE, pulmonary embolism; PFT, pulmonary
ement; RH Cath, right heart catheterization; RVE, right ventricular enlargement;
ophageal echocardiography; VHD, valvular heart disease; and VQ Scan, ventilation-ograp
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensionre being explored to assess RV mass, volumes, and func-
ion, and in the area of chronic thromboembolic pulmonary
ypertension (CTEPH). Promising MR markers of
AH include change in the ratio of septal curvature, RV
jection fraction, RV volume, noninvasively measured car-
iac index, and delayed hyperenhancement (measured using
adolinium-enhanced MR imaging) (93).
LASSIFICATION
n most cases, PH is discovered during evaluation for
ymptoms (dyspnea, fatigue, chest pain, syncope, or edema).
nce suspected, based on echocardiographic criteria, a
earch for a potential underlying association or cause must
e undertaken in order to treat the PH appropriately and
dvise regarding prognosis and adjunctive therapy. At the
utset, all causes of PAH (Group 1) and non-PAH (Groups
to 5) PH must be considered. The algorithm in Figure 3
eflects the fact that both appropriate assessment for under-
ying cause (Table 1) as well as the hemodynamic pattern
see the following text) are required.
It is important to exclude other disorders that cause PH
uring the diagnostic evaluation, as etiology of PH dictates
reatment. While much of the evaluation is self evident in
igure 3, special emphasis on excluding CTEPH is appro-
riate. Approximately 3% to 4% of those who experience an
able 3. Approach Following Substrate Recognition
Substrate F
MPR2 mutation Echocardiogram yearl
evidence of PAH (hi
right heart chambe
st degree relative of patient with BMPR2 mutation
or within pedigree of 2 or more patients with a
diagnosis of PAH
Genetic counseling an
genotyping; proceed
ystemic sclerosis Echocardiogram yearl
evidence of PAH (hi
right heart chambe
IV infection Echocardiogram if sym
RHC if echo demon
ventricular systolic
enlargement)
ortal hypertension Echocardiogram if OL
demonstrates evide
systolic pressure or
rior appetite suppressant use (fenfluramine) Echocardiogram only
ongenital heart disease with shunt Echocardiogram and R
repair of defect if si
ecent acute pulmonary embolism Ventilation-perfusion (
if symptomatic; pul
ickle cell disease Echocardiogram yearl
evidence of PAH (hi
right heart chambe
MPR2 indicates bone morphogenic protein receptor 2; HIV, human immunodeficiency virus; L-R,
eart catheterization.cute pulmonary embolus (PE) do not fully resolve the ohrombus burden, despite anticoagulation, and go on to
evelop CTEPH (103). On the other hand, one half of
hose patients who are ultimately diagnosed with CTEPH
o not give a history of an acute PE. CTEPH has recently
een reviewed (104). The screening test of choice to exclude
TEPH in the patient with otherwise unexplained dyspnea
nd PH is the radionuclide perfusion scan. A normal or very
ow probability essentially excludes CTEPH, and a high
robability scan warrants further evaluation with a pulmo-
ary angiogram. Clinical judgment is required for those
ith a nondiagnostic scan, and based on the clinical
uspicion and presence of underlying parenchymal lung
isease, further evaluation may be warranted. At the
urrent time, spiral or PE protocol CT, while excellent
or excluding an acute PE in the appropriate clinical
etting, is less sensitive than the perfusion scan to exclude
TEPH. It is important to rule out CTEPH even in
hose with an underlying risk factor for PAH, such as the
cleroderma spectrum of diseases population, as the
herapeutic implications of the diagnosis are substantial.
n some patients, such as those with parenchymal lung
isease and a low likelihood of CTEPH, the perfusion
can may be difficult to interpret and a PE protocol CT
ay be useful. CT is also useful to determine the extent
Assessment Rationale
if echocardiogram demonstrates
ht ventricular systolic pressure or
gement)
Early detection of PAH; 20% chance of
developing PAH
mmendation for BMPR2
ove if positive
Autosomal dominant transmission
if echocardiogram demonstrates
ht ventricular systolic pressure or
gement)
About 8% (by RHC) 27% (by
echocardiogram screening)
prevalence of PAH in systemic
sclerosis (27,78)
s or signs suggestive of PAH;
s evidence of PAH (high right
re or right heart chamber
0.5% prevalence of PAH
idered; RHC if echocardiogram
f PAH (high right ventricular
heart chamber enlargement)
4% prevalence of PAH in candidates
for OLT; PAH is predictive of poor
OLT outcome
ptomatic Incidence of PAH is approximately
0.005% if agent used greater than
3 months
t time of diagnosis; consider
nt L-R shunt present
High probability of PAH developing in
unrepaired shunt (Eisenmenger
syndrome)
cintigraphy 3 months after event
y angiogram if positive
3% risk of chronic thromboembolic
PH; negative VQ scan excludes
chronic thromboembolism
if echocardiogram demonstrates
ht ventricular systolic pressure or
gement)
Increased mortality if PH present,
early detection of PH, 30% develop
PH, about 10% develop PAH
right; OLT, orthotopic liver transplantation; PAH, pulmonary arterial hypertension; and RHC, righturther
y; RHC
gh rig
r enlar
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gh rig
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619gy, PE protocol CT may replace perfusion scanning to
creen for CTEPH in the future.
ONFIRMATION
lthough Doppler echocardiography and associated find-
ngs may suggest the presence of PH, RHC (with an
ccurate assessment of PVR) is required to confirm the
iagnosis and to define the hemodynamic profile in greater
etail and accuracy.
.6. Invasive Hemodynamic Assessment
areful invasive assessment of pulmonary hemodynamics is
ivotal in the evaluation of any patient with suspected PAH.
he utility of RHC is dependent on the accuracy and
ompleteness of the data obtained. Essential components of
he RHC are summarized in Table 6.
Many of the causes of elevated PA pressure (PH) are not
able 4. Features of the Physical Examination Pertinent to the
Sign
Physical Signs Tha
ccentuated pulmonary component of S2 (audible at apex in over 90%)
arly systolic click
idsystolic ejection murmur
eft parasternal lift
ight ventricular S4 (in 38%)
ncreased jugular “a” wave
Physical Signs That Sug
oderate to severe PH
Holosystolic murmur that increases with inspiration
Increased jugular v waves
Pulsatile liver
Diastolic murmur
Hepatojugular reflux
dvanced PH with right ventricular failure
Right ventricular S3 (in 23%)
Distention of jugular veins
Hepatomegaly
Peripheral edema (in 32%)
Ascites
Low blood pressure, diminished pulse pressure, cool extremities
Physical Signs That Suggest Possibl
entral cyanosis
lubbing
ardiac auscultatory findings, including systolic murmurs, diastolic murmurs,
opening snap, and gallop
ales, dullness, or decreased breath sounds
ine rales, accessory muscle use, wheezing, protracted expiration, productive co
besity, kyphoscoliosis, enlarged tonsils
clerodactyly, arthritis, telangiectasia, Raynaud phenomenon, rash
eripheral venous insufficiency or obstruction
enous stasis ulcers
ulmonary vascular bruits
plenomegaly, spider angiomata, palmary erythema, icterus, caput medusa,
ascites
H indicates pulmonary hypertension.aused by pulmonary vascular pathology. For example, PH commonly occurs with high transpulmonary flow in the
etting of exercise, anemia, pregnancy, sepsis, portopulmo-
ary syndrome, or thyrotoxicosis. In these conditions, the
ulmonary vascular bed is anatomically normal and the PH
esolves when the cardiac output returns to normal levels.
he transpulmonary gradient (PAP mean-wedge) is signif-
cantly elevated in PAH patients, but not in patients whose
H is due to increased cardiac output, left heart myocardial,
r valvular disease. There is a small subset of the patients
ith diseases causing passive PH who have a disproportion-
te elevation of PVR (identified somewhat arbitrarily by
VR greater than 3 Wood units and a transpulmonary
radient greater than 20 mm Hg) (see Section 9, Non-
ulmonary Arterial Hypertension Pulmonary Hypertension
opulations).
It was the committee’s majority opinion that diagnostic
luation of PH
Implication
ect Severity of PH
High pulmonary pressure increases force of pulmonic valve closure
Sudden interruption of opening of pulmonary valve into high-pressure artery
Turbulent transvalvular pulmonary outflow
High right ventricular pressure and hypertrophy present
High right ventricular pressure and hypertrophy present
Poor right ventricular compliance
Moderate to Severe PH
Tricuspid regurgitation
Pulmonary regurgitation
High central venous pressure
Right ventricular dysfunction
Right ventricular dysfunction or tricuspid regurgitation or both
Right ventricular dysfunction or tricuspid regurgitation or both
Reduced cardiac output, peripheral vasoconstriction
erlying Cause or Associations of PH
Abnormal V/Q, intra-pulmonary shunt, hypoxemia, pulmonary-to-systemic
shunt
Congenital heart disease, pulmonary venopathy
Congenital or acquired heart or valvular disease
Pulmonary congestion or effusion or both
Pulmonary parenchymal disease
Possible substrate for disordered ventilation
Connective tissue disorder
Possible venous thrombosis
Possible sickle cell disease
Chronic thromboembolic PH
Portal hypertensionEva
t Refl
gest
e Und
ughriteria for PAH stated in several recent guidelines should
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensione clarified as requiring elevated PVR as opposed to simply
n elevated mPAP in the setting of a normal left heart filling
ressure (105,106). PVR is a more robust diagnostic crite-
ion for PAH because it reflects the influence of transpul-
onary gradient and cardiac output and is only elevated if
he vascular obstruction occurs within the precapillary pul-
onary circulation. PVR is a useful measure to apply to
atients with increased mPAP. PVR distinguishes passive
H (elevated mPAP, normal PVR) from PH caused by
ulmonary vascular disease (elevated mPAP, elevated PVR).
y definition, PVR and mPAP are both elevated in PAH.
owever, PVR can also be elevated in patients with valve
isease or LV disease (some of whom have an element of
ulmonary artery disease, in addition to passive PH). PAH
emains a diagnosis of exclusion. After excluding lung
isease, thromboembolic disease, LV disease, or valve dis-
ase, the diagnostic criteria for PAH requires both a mPAP
reater than 25 mm Hg and a PVR greater than 3 Wood
nits. In such a setting, PAH is the most likely cause of the
H. Invasive hemodynamic studies are essential to establish
correct diagnosis: therefore, the committee cautions
gainst over-reliance on noninvasive, echocardiographically
erived estimates of PAP. If one considers a general
ardiology population, PAP will be elevated much more
ften due to left heart diseases (systolic or diastolic dysfunc-
ion) or valvular disease than by true pulmonary vascular
Prominent Central
Pulmonary Artery
Peripheral
Hypovascularity
Right Descending 
Pulmonary Artery
A
B
igure 4. Chest X-Ray and ECG in PAH
ostero-anterior and lateral chest X-ray (top) shows decreased peripheral lung vascu
atient with idiopathic PAH. ECG (bottom) of the same patient reveals right atrial en
omplex. ECG indicates electrocardiogram; and PAH, pulmonary arterial hypertensionisease. It was the minority opinion that the requirement for wn elevation in PVR greater than 3 Wood units not be
ncluded as a component of the hemodynamic definition of
AH. These committee members cited primarily high flow
onditions as potential exceptions to this definition, includ-
ng uncorrected CHD, sickle cell disease, and portopulmo-
ary hypertension. At certain stages of these disorders, some
atients might have elevated mPAP, but a normal PVR due
o a high cardiac output, yet have pulmonary vascular
isease histologically. Ultimately, it may be proposed that
levated PAP alone is sufficient to diagnosis PH, whereas
VR must be included to diagnose PAH.
.7. Right Heart Catheterization
ome patients initially suspected of having PAH will not
equire catheterization, having had an alternative diagnosis
stablished by noninvasive testing. However, all patients
hat are still suspected of having PAH after noninvasive
valuation should undergo RHC prior to initiation of
herapy. The utility of RHC is dependent on the accuracy
nd completeness of the data obtained. The sequence in this
iagnostic algorithm, with the RHC reserved for those who
fter noninvasive screening are considered “probable PAH
atients,” allows the procedure to be focused on measuring
AP, calculating PVR, and performing vasodilator testing.
hile RHC remains the gold standard assessment of
emodynamics in PH, most often, measurements are made
RV 
Enlargement
rkings, hilar pulmonary artery prominence, and right ventricular enlargement of a
ent, right ventricular hypertrophy and strain, and right axis deviation of the QRSlar maith the patient at rest, and may not reflect the true extent
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ifficult, both to perform and interpret, and while not used
outinely in most clinical settings, is an area of active
nvestigation.
.8. Components of an Optimal Invasive Evaluation
he rigorous diagnosis of PAH in the catheterization
aboratory should include wedging a balloon flotation cath-
ter in several segments of the pulmonary vasculature.
easurement of the wedge pressure, a surrogate for left
trial pressure in the absence of pulmonary vein obstruction,
s useful to exclude PH due to left heart diseases; the wedge
ressure may be normal in some segments in pulmonary
eno-oclusive disease. The wedge pressure should be mea-
ured at end-expiration of a spontaneous respiratory cycle. If
n optimal wedge pressure tracing cannot be obtained, or if
here is any question about the accuracy of the wedge
ressure tracing, a measurement of LV end-diastolic pres-
igure 5. Echocardiographic Features of PAH
A) Parasternal short axis view. (B) Apical 4 chamber view. Common echocardio-
raphic findings in PAH include: right atrial enlargement; right ventricular enlarge-
ent; abnormal contour, flattening, or reverse curvature of the interventricular
eptum; and underfilled left heart chambers. LA indicates left atrial; LV, left ventric-
lar; RA, right atrial; and RV, right ventricular. Reprinted with permission from the
niversity of Michigan.ure should be obtained. As PCWP measurements are
I
sometimes inaccurate, a direct measurement of LVEDP is
ecommended in patients in whom left heart disease is the
ikely etiology, such as those with symptoms of orthopnea or
ssociated risk factors. Thermodilution cardiac output, if
esults are consistent when measured in triplicate, can be
dequate in PAH patients, provided there is not severe
ricuspid regurgitation or an intracardiac shunt. Indeed,
here are data suggesting that even in the presence of low
ardiac output and significant tricuspid regurgitation the
hermodilution technique correlates well with the Fick
echnique in patients with PH (107). However, because
evere tricuspid regurgitation is not uncommon in PAH, a
ick determination of cardiac output may be required.
otential errors related to the Fick measurement include
ssumptions and inaccurate measurements of oxygen con-
umption. Without a reliable measure of cardiac output, the
bility to calculate PVR and to interpret acute vasodilator
esting is compromised.
able 5. Causes for PH Identified by Echocardiography
onditions That Predispose to Pulmonary Hypertension
Congenital or acquired valvular disease (MR, MS, AS, prosthetic valve
dysfunction)
Left ventricular systolic dysfunction
Impaired left ventricular diastolic function (hypertensive heart disease, HCM,
Fabry’s disease, infiltrative cardiomyopathies)
Other obstructive lesions (coarctation, supravalvular AS, subaortic membrane,
cor triatriatum)
Congenital disease with shunt (ASD, VSD, coronary fistula, patent ductus
arteriosus, anomalous pulmonary venous return)
Pulmonary embolus (thrombus in IVC, right-sided cardiac chamber, or PA;
tricuspid or pulmonic valve vegetation)
Pulmonary vein thrombosis/stenosis
indings That Suggest Specific Disease Entity
Left-sided valve changes (SLE, anorexigen use)
Intra-pulmonary shunts (hereditary hemorrhagic telangiectasia)
Pericardial effusion (IPAH, SLE, systemic sclerosis)
S indicates aortic stenosis; ASD, atrial septal defect; HCM, hypertrophic cardiomyopathy; IPAH,
diopathic pulmonary arterial hypertension; IVC, inferior vena cava; MR, mitral regurgitation; MS,
itral stenosis; PA, pulmonary artery; SLE, systemic lupus erythematosus; and VSD, ventricular
eptal defect.
able 6. Essential Components of Invasive Hemodynamic
ssessment
xygen saturations (SVC, IVC, RV, PA, SA)
ight atrial pressure
ight ventricular pressure
ulmonary artery pressure, systolic, diastolic, mean
ulmonary arterial wedge pressure, left atrial pressure, or left ventricular
end-diastolic pressure
ardiac output/index
ulmonary vascular resistance
ystemic blood pressure
eart rate
esponse to acute vasodilatorVC indicates inferior vena cava; PA, pulmonary artery; RA, right atrium; RV, right ventricle; SA,
ystemic artery; and SVC, superior vena cava.
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lthough RHC and pulmonary angiography are invasive,
hey can be performed safely by experienced operators even
n patients with severe PH and right heart failure. A recent
tudy retrospectively reviewed over 5,000 RHC procedures
nd prospectively collected an additional 1,500 procedures,
or a total of 7,218 RHC procedures performed at 20 major
ulmonary vascular centers over a 5-year period (108). The
esults from the retrospective and the prospective analyses
ere almost identical. Overall, 76 (1.1%) serious events were
eported. The most frequent complications were related to
enous access (e.g., hematoma, pneumothorax), followed by
rrhythmias and hypotensive episodes related to vagal reac-
ions or pulmonary vasoreactivity testing. The vast majority
f these complications were mild to moderate in intensity
nd resolved either spontaneously or after appropriate in-
ervention. Four fatal events were recorded in association
ith any of the catheter procedures, only 1 of which was
irectly related to the performance of the procedure, result-
ng in an overall procedure-related mortality of 0.05%.
.10. Spontaneous Variability in
ulmonary Artery Pressure
ascular pressure measurements obtained during RHC may
e influenced by ventilation in 2 ways that must be consid-
red in the interpretation of hemodynamic variables: 1)
ormal fluctuations in PAP and flow that occur as a
unction of phasic, dynamic changes during breathing; and
) larger, partly artifactual swings in pressure that may occur
uring exercise, hyperventilation, valsalva, or in the setting
f chronic lung disease. The normal decrease in intratho-
acic pressure that is caused by inspiration slightly reduces
AP relative to atmospheric pressure and increases venous
eturn to the right heart, resulting in an increase in pulmo-
ary blood flow. With passive exhalation, intrathoracic
ressure approaches atmospheric pressure. These effects in
ormal individuals are small, but become accentuated dur-
ng assisted ventilation or in patients with lung disease. Our
onsensus was that physicians can reduce variability by
onsistently measuring pressures over 2 to 3 respiratory
ycles at end-exhalation when intrathoracic pressure is
losest to atmospheric.
.11. Ambulatory Measurement of
ulmonary Hemodynamics
espite the “definitive” role of RHC, the procedure is
able 7. Agents for Acute Vasodilator Testing
Epoprostenol
oute of Administration Intravenous infusion Intraveno
ose Titration 2 ng/kg/min every 10 to 15 min 50 mcg/
ose Range 2 to 10 ng/kg/min 50 to 25
ide Effects Headache, nausea, lightheadedness Dyspnea,
V indicates atrioventricular.arried out under artificial conditions that may not reflect bulmonary hemodynamic conditions during the patients’
aily lives. Thus, using a single value for a hemodynamic
arameter as a baseline assessment of disease that is known
o progress or against which to judge the effects of therapy
isks mistaking spontaneous variability for a meaningful
ifference (or lack of difference). Ongoing investigation of
n implantable monitor that provides continuous RV and
A hemodynamics (109,110) may provide a more reliable
eans of assessing the course of selected patients (111).
.12. Acute Vasodilator Testing
he rationale for vasodilator testing in the diagnostic
valuation of PAH patients is based on 2 factors: 1) acute
asodilator responsiveness identifies patients with a better
rognosis; and 2) responders are more likely to have a
ustained beneficial response to oral calcium channel block-
rs than nonresponders and could be treated with these less
xpensive drugs (84,112).
.13. Agents for Acute Vasodilator Testing
cute vasodilator testing is usually performed during the
ame procedure as the diagnostic catheterization. The
deal vasodilator agent for PAH is selective for the
ulmonary circulation and has rapid onset and offset of
ffect. Acute vasodilator testing is most commonly per-
ormed using iNO (113), intravenous epoprostenol (114),
r intravenous adenosine (115) (Table 7). Although there
s no evidence-based guideline for selection of vasodila-
ors, it is our consensus that iNO is the preferred
asodilator, while intravenous epoprostenol and intrave-
ous adenosine are acceptable alternatives. The optimal
ose of iNO has not been established by a clinical trial.
owever, in clinical practice, it is common to use doses
f 20 to 40 ppm for 5 minutes. Repeat hemodynamics
hould be obtained while on iNO and it may then be
iscontinued, without weaning, after the hemodynamic
ata are obtained. The choice of vasodilator remains one
f operator preference; however, one should not use
alcium channel blockers, sodium nitroprusside, or ni-
rates for acute vasodilator testing as the safety and
fficacy of these agents for acute vasodilator testing has
ot been established in PAH patients.
.14. Definition of Responders to Acute Vasodilator
esting in Pulmonary Arterial Hypertension
he definition of a “positive” response is controversial.
sing the definition of a positive response as a 20% fall in
osine Nitric Oxide
usion Inhaled
n every 2 min None
/kg/min 10 to 80 ppm
pain, AV block Increased left heart filling pressure in susceptible patientsAden
us inf
kg/mi
0 mcg
chestoth PAP and PVR with either intravenous epoprostenol or
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619NO, Sitbon et al. (84) found only 70 responders out of 557
atients with IPAH (12.6%), a rate lower than that reported
y Rich et al. (83) in 64 IPAH patients (26.6%) or by Weir
t al. (116) in the NIH registry (55%) (83,84,116). More
mportantly, Sitbon et al. (81) observed that only 38 of the
0 acute responders (6.8% of the total IPAH study popu-
ation) displayed long-term improvement with calcium
hannel blocker therapy. Logistic regression analysis iden-
ified the following variables achieved during acute vasodi-
ator administration that were associated with long-term
alcium channel blocker therapy success: a reduction in
PAP to less than 37 mm Hg, a fall in mPAP greater than
1%, a reduction in PVR to less than 6.7 Wood units, and
fall in PVR greater than 45%. These authors noted,
owever, that 6 long-term responders to calcium channel
lockers failed to meet these a posteriori criteria of acute
esponse.
Based largely on the data from the Sitbon series, the
uropean Society of Cardiology and the ACCP guidelines
roposed that an acute response to acute vasodilator testing
e defined as a decrease in mPAP by at least 10 mm Hg to
n absolute level of less than 40 mm Hg without a decrease
n cardiac output (105,117). While the sensitivity of these
riteria are insufficient to capture all patients who may be
esponsive to long-term calcium channel blocker therapy,
hey are sufficiently specific to identify patients who are
nlikely to benefit from this form of therapy and for whom
ther treatments are appropriate. There are little data on
hich to make recommendations in the patient with an
PAP less than 40 mm Hg at baseline. In the event that
uch a patient had a substantial (less than 20%) reduction in
PAP in the setting of a normal cardiac output, it would be
easonable to administer a trial of calcium channel blockers
nd assess the clinical response.
.15. Vasodilator Testing in Pulmonary Arterial
ypertension Subsets
he best data supporting the use of acute vasodilator testing
o determine prognosis comes from IPAH patients. Limited
ata exist, but suggest that responders to vasodilators are
are among other groups, including those with the BMPR2
enotype (118) anorexigen induced PAH (119), and those
ith scleroderma spectrum of diseases (120). Caution is
equired in testing patients with concomitant LV disease, as
ulmonary edema in response to iNO or epoprostenol has
een reported in patients with stable heart failure due to left
eart disease (121) or with pulmonary venoocclusive disease,
ossibly relating to vasodilatation and flooding of the
apillary bed in response to a highly selective arterial
asodilator.
ETERMINING TREATMENT
n general, distinguishing optimal treatment strategies
roadly depends on the diagnostic categories, hemodynam-
cs, severity of the disease, and associated findings. (See
ection 6.15.) t.16. Summary
e recommend the following, with respect to diagnostic
ssessment for PH:
1. Certain individuals with predisposing risk factors war-
rant periodic screening for PAH (Table 3).
2. Patients in whom there is an index of suspicion of PH
based on history, risk factor assessment, physical exam-
ination, CXR, and ECG warrant further evaluation.
3. The most appropriate initial study to evaluate patients
in whom PH is suspected is a Doppler echocardiogram.
4. Evaluation for other etiologies of PH, for example,
CTEPH, is appropriate in all instances (Figure 3).
5. The diagnosis of PAH requires confirmation by a
complete RHC. The hemodynamic definition of PAH
is an mPAP greater than 25 mm Hg, a PCWP/LAP/
LVEDP less than or equal to 15 mm Hg, and a PVR
greater than 3 Wood units.
6. Acute vasodilator testing should be performed in all
IPAH patients who might be considered potential
candidates for long-term therapy with oral calcium
channel blockers. IPAH patients in whom chronic
calcium channel blocker therapy would not be consid-
ered, such as those with overt right heart failure or
hemodynamic instability, need not undergo acute vaso-
dilator testing.
7. Acute vasodilator testing should be performed at cen-
ters experienced in the administration of these agents
and in the interpretation of the results.
8. The definition of an acute response that may warrant
initiation of long-term therapy with oral calcium chan-
nel blockers is a decrease in mPAP of at least 10 mm
Hg to an absolute mPAP of less than 40 mm Hg
without a decrease in cardiac output. Although this
stringent definition may misclassify a few patients who
could be treated effectively with long-term oral calcium
channel blockers, it will reliably identify those who are
least likely to benefit from oral calcium channel blocker
therapy and, therefore, provides the greatest degree of
safety.
9. Patients with PAH due to conditions other than IPAH
have a very low rate of long-term responsiveness to oral
calcium channel blocker therapy. Accordingly, the de-
cision to proceed with acute testing in such patients
should be individualized.
0. Acute vasodilator testing is not indicated, and may be
harmful, in patients with significantly elevated left heart
filling pressures.
. Evidence-Based Treatment Algorithm
reatment of PAH has evolved considerably over the past
ecade due in part to advances in knowledge of the basic
athobiology of the disease and the availability of agents
hat target known derangements in the pathobiologic pro-
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensioness. Treatment algorithms have been formulated by the
CCP, the European Society of Cardiology, and a panel of
xperts who convened at the Third World Symposium on
ulmonary Hypertension held in Venice, Italy, in 2003
105,117,122). Notably, the clinical data on which these
lgorithms are based were conducted primarily in patients
ith IPAH and PAH related to connective tissue disease
nd anorexigens. A smaller number of trials have also
ncluded PAH related to CHD and HIV. These clinical
rial data cannot necessarily be extrapolated to those with
ther types of PH, including those related to left heart
isease and hypoxemic lung disease, or other types of WHO
roup I PAH.
Treatment goals in PAH patients are numerous. Improv-
ng the patients symptoms, which commonly include dys-
nea, is paramount. Enhancing functional capacity, mea-
ured objectively by an assessment of exercise endurance
uch as the 6MW or a cardiopulmonary exercise test, is also
treatment objective. Given the severe hemodynamic de-
angements in PAH, lowering PAP and normalizing car-
iac output are important treatment goals. Another impor-
ant goal is to reverse or at least prevent progression of the
isease, that is, prevent the need for more therapies,
ospitalization, and lung transplantation. Last, we strive to
mprove survival, which, while important, is rarely an end
oint in clinical trials of PAH treatment due to the small
umber of patients and limited duration of the trials.
.1. General Measures
hile limited data exist on which to base recommendations
egarding exercise, we encourage low level graded aerobic
xercise, such as walking, as tolerated. Intensive exercise
raining was studied in a randomized fashion in 30 patients
ho were stable on disease-targeted medical therapy. After
5 weeks, those who received exercise training demon-
trated improvements in 6MW test, quality of life, func-
ional class, and peak oxygen consumption (123). Patients
re advised to avoid heavy physical exertion or isometric
xercise (straining against a fixed resistance) as this may
voke exertional syncope. Exposure to high altitudes may
ontribute to hypoxic pulmonary vasoconstriction and may
ot be well tolerated. Similarly, some patients may require
xygen on commercial aircraft. While there are no data
rom controlled trials, we recommend that patients with a
reflight pulse oximetry saturation of less than 92% should
eceive supplemental oxygen (124). A sodium restricted diet
less than 2,400 mg per day) is advised and is particularly
mportant to manage volume status in patients with RV
ailure. Routine immunizations, such as those against influ-
nza and pneumococcal pneumonia, are advised.
The hemodynamic fluctuations of pregnancy, labor, de-
ivery, and the postpartum period are potentially devastating
n PAH patients. Some series have demonstrated a 30% to
0% maternal mortality rate (125). Current guidelines
ecommend that pregnancy be avoided or terminated early
n women with PAH (117). It is important to discuss dffective methods of birth control with women with PAH of
hild-bearing potential, although the preferred method is
ot clear. While estrogen-containing contraceptives may
ncrease risk of venous thromboembolism, currently avail-
ble lower-dose preparations with concurrent warfarin an-
icoagulation are a reasonable option. Surgical sterilization
nd barrier methods are also alternatives.
.2. Background Therapy
everal agents are commonly used in the treatment of PAH
espite relatively little controlled trial data. Anticoagulants
ave been studied in 3 noncontrolled observational series in
atients with primarily IPAH, 1 prospective and 2 retro-
pective (83,85,126). An improvement in survival with
arfarin anticoagulation has been observed. Per our com-
ittee’s consensus, we recommend warfarin anticoagulation
n IPAH patients titrated to an international normalized
atio of 1.5 to 2.5. Few data exist to guide recommendations
or patients with associated forms of PAH. We recommend
nticoagulation in such patients with more advanced dis-
ase, such as those on continuous intravenous therapy, in
he absence of contraindications. Diuretics are indicated to
anage RV volume overload, which is commonly manifest
s elevated jugular venous pressure, lower extremity edema,
nd abdominal distention. In some cases, intravenous di-
retics are required. Serum electrolytes and renal function
hould be closely monitored. As hypoxemia is a potent
ulmonary vasoconstrictor, most experts recommend oxy-
en supplementation to maintain oxygen saturation above
0%. There are few data pertaining to the use of digoxin in
AH. One acute study demonstrated that the administra-
ion of intravenous digoxin in IPAH patients produced a
odest increase in cardiac output and a reduction in
irculating norepinephrine levels, although longer-term data
re not available (127). Digoxin is sometimes used in those
atients with right heart failure and a low cardiac output and
n patients with atrial arrhythmias.
.3. Calcium Channel Blockers
he enthusiasm for the use of calcium channel blockers in
PAH dates back to 1992 with the publication of a study
hat demonstrated 95% 5-year survival in a very select group
f patients with IPAH who exhibited an acute vasodilator
esponse to calcium channel blockers (83). More recent data
egarding vasodilator testing were discussed previously (Sec-
ion 6). The current consensus definition of a response is
ow defined as a fall in mPAP of greater than or equal to 10
m Hg, to an mPAP less than or equal to 40 mm Hg, with
n unchanged or increased cardiac output. While many
xperts also perform vasodilator testing on patients with
ssociated forms of PAH, true responders are very uncom-
on. Patients who meet these criteria may be treated with
alcium channel blockers and should be followed closely for
oth safety and efficacy of calcium channel blocker therapy.
f a patient who meets the definition of an acute response
oes not improve to functional class I or II on calcium
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619hannel blocker therapy, the patient should not be consid-
red a chronic responder, and alternative or additional PAH
herapy should be instituted. Long acting nifedipine, dilti-
zem, or amlodipine are the most commonly used calcium
hannel blockers. Due to its potential negative inotropic
ffects, verapamil should be avoided.
.4. Prostanoids
s previously discussed, prostacyclin synthase is reduced in
AH patients, resulting in inadequate production of pros-
acyclin I2, a vasodilator with antiproliferative effects. Ad-
inistering prostanoids has been a mainstay of PAH
herapy for more than a decade. There are currently 3
ommercially available prostanoids: epoprostenol, treprosti-
il, and iloprost.
.5. Epoprostenol
ntravenous epoprostenol improves functional class, exercise
olerance, hemodynamics, and survival in IPAH. An open
abel, randomized trial of 81 functional class III and IV
PAH patients demonstrated significant improvements in
he primary end point of 6MW test (32 m increase with
poprostenol versus 15 m decrease with conventional ther-
py alone, placebo-corrected change of 47 m) and in
econdary end points including hemodynamics and quality
f life (76). Eight patients, all of whom were randomized to
onventional therapy alone, died over the course of the
2-week trial, suggesting a survival benefit of the drug (p
.003). Longer-term observational studies have confirmed
he chronic benefits of intravenous epoprostenol in IPAH
atients. In a series of 178 functional class III and IV IPAH
atients, Sitbon et al. (78) reported improved survival with
ntravenous epoprostenol compared to historical controls
ith 1-, 2-, 3-, and 5-year survival rates of 85%, 70%, 63%,
nd 55%, respectively. Similarly, in a series of 162 functional
lass III and IV patients, intravenous epoprostenol resulted
n improved survival as compared with the predicted survival
ased on the NIH equation with 1-, 2-, 3-, and 5-year
urvival rates of 88%, 76%, 63%, and 56%, respectively (77).
mprovements in functional class, exercise endurance, and
emodynamics were noted in both of these observational
tudies.
Intravenous epoprostenol has also been evaluated in PAH
ssociated with the scleroderma spectrum of diseases. A
ulticenter, open label, randomized trial demonstrated
arked improvements in exercise endurance (median
hange 46 m with epoprostenol, 48 m with conven-
ional therapy alone) and hemodynamics, but no effect on
ortality after 12 weeks of therapy (80). Observational
eries have also reported favorable effects of intravenous
poprostenol in patients with numerous forms of associated
AH (72,79,128–131).
Epoprostenol must be delivered by continuous intrave-
ous infusion. Each patient must learn the techniques of
terile preparation of the medication, operation of the
mbulatory infusion pump, and care of the central venous satheter. Intravenous epoprostenol is commonly started in
he hospital at a dose of 2 ng/kg/min and the dose is further
djusted up based on symptoms of PAH and side effects of
he drug. While the dosing must be highly individualized,
ost experts believe that the optimal dose range for chronic
herapy is between 25 and 40 ng/kg/min for most adult
atients, when used as monotherapy. Chronic overdose
ometimes results in high cardiac output failure, and the
ong-term consequences of this are unknown and may be
etrimental (132). Common side effects include headache,
aw pain, flushing, nausea, diarrhea, skin rash, and muscu-
oskeletal pain. Infections and infusion interruptions can be
ife-threatening. Given its considerable complexity, epopro-
tenol use should be limited to centers experienced with its
dministration and with systematic follow-up of patients.
.6. Treprostinil
reprostinil is a stable prostanoid with an elimination half
ife of about 4.5 hours that was first studied using subcuta-
eous administration during a 12-week, placebo controlled,
ulticenter, randomized trial of 470 patients with func-
ional class II, III, or IV PAH (IPAH, connective tissue
isease of CHD related) (133,134). Subcutaneous trepros-
inil resulted in a modest but statistically significant between
reatment group median increase of 16 m of the 6MW test,
hich was dose related. The change in 6MW test was a
esult of improvement in the group receiving treprostinil,
nd there was no change in 6MW test in the placebo group.
dverse effects included pain or erythema at the site of the
ubcutaneous infusion in 85% of patients. Other common
ide effects include headache, diarrhea, rash, and nausea.
he Food and Drug Administration (FDA) approved
ubcutaneous treprostinil in 2002 for use in functional class
I, III, and IV PAH.
More recently, intravenous treprostinil has been studied
n an open label, uncontrolled fashion. Tapson et al. (135)
eported an 82 m improvement (from 319 plus or minus
2 m to 400 plus or minus 26 m, p0.001) of 6MW test in
6 functional class III or IV PAH patients treated with
ntravenous treprostinil as monotherapy. In a similar open
abel trial, Gomberg-Maitland et al. (136) transitioned 31
unctional class II and III PAH patients from intravenous
poprostenol to intravenous treprostinil. Twenty-seven pa-
ients completed the transition, and 4 were transitioned
ack to epoprostenol. Exercise endurance as measured by
he 6MW test was maintained among the patients complet-
ng the transition (438 plus or minus 16 m at baseline, 439
lus or minus 16 m at week 12), although there was a
odest increase in PAP and decrease in CI. Notably, the
ose of intravenous treprostinil at the end of 12 weeks was
ore than twice the dose of intravenous epoprostenol at the
tart of the study (83 ng/kg/min versus 40 ng/kg/min). In
004, the FDA approved the use of intravenous treprostinil
n functional class II, III, and IV PAH patients in whom
ubcutaneous infusion is not tolerated. Intravenous trepro-
tinil has a side effect profile similar to intravenous epopro-
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ecently raised the concern for an increased risk of blood-
tream infections, particularly with gram-negative organ-
sms, in patients receiving intravenous treprostinil (137).
atheter infections can be life threatening. The overall
nfection rate with treprostinil was significantly greater than
hat of epoprostenol (incidence ratio 2.57, 95% confidence
nterval: 1.81 to 3.64), with a higher rate of gram-negative
acteremia. There was considerable variability from one site
o another. Inclusion of the index site that made the initial
bservation, the retrospective nature of the study, and site to
ite variation, with some just including treprostinil patients
s opposed to both epoprostenol and treprostinil, are among
he limitations of this observation. This finding has led to
evised recommendations regarding catheter care (138).
linically, it also highlights the importance in the choice of
mpiric antibiotics in those suspected of having a blood-
tream infection. Investigational trials with both inhaled
nd oral formulations of treprostinil are ongoing. Given the
omplexity of administration of both intravenous and sub-
utaneous treprostinil, administration should be limited to
enters with experience with this agent.
.7. Iloprost
loprost is a prostanoid that can be delivered by an adaptive
erosol device that has been studied in a 12-week, multi-
enter, placebo-controlled, randomized trial of 207 func-
ional class III and IV patients with either IPAH, PAH
ssociated with scleroderma spectrum of diseases or appetite
uppressants, or PH related to inoperable chronic throm-
oembolic disease (139). This study utilized a novel com-
osite end point of improvement in functional class by at
east 1 level and improvement in 6MW test by at least 10%
n the absence of clinical deterioration. The combined
linical end point was met by 16.8% of those receiving
nhaled iloprost compared to 4.9% of those receiving pla-
ebo (p0.007). The treatment effect on the 6MW test was
mean increase of 36 m in favor of iloprost (p0.004). This
as attributable to both an improvement in the iloprost
roup and a deterioration in the placebo group. Longer-
erm outcomes with iloprost monotherapy are conflicting.
n a study of 24 iloprost-treated IPAH patients, Hoeper et
l. (140) reported sustained benefits in exercise capacity and
emodynamics at 1 year. More recently, Opitz et al. (141)
eported event-free survival rates of 53%, 29%, and 20% at
, 2, and 3 years, respectively, in IPAH patients treated with
loprost monotherapy. Common side effects of inhaled
loprost include cough, headache, flushing, and jaw pain.
loprost was approved by the FDA in 2004 for functional
lass III and IV PAH.
.8. Endothelin Receptor Antagonists
ndothelin-1 is a vasoconstrictor and a smooth muscle
itogen that may contribute to the development of PAH.
ttempting to treat PAH by endothelin receptor blockades a promising approach supported by evidence of the mathogenic role of endothelin-1 in PAH, as discussed in
ection 3.
.9. Bosentan
n an initial effort to evaluate bosentan in PAH, a relatively
mall, randomized, double-blind, placebo-controlled, mul-
icenter study of 32 functional classes III or IV IPAH or
cleroderma spectrum of diseases associated patients PAH
ere randomized to receive bosentan versus placebo (2:1
atio) (142). After 12 weeks, the 6MW test improved by
0 m (from 360 plus or minus 19 m at baseline to 430 plus
r minus 14 m at week 12; p0.05) in the bosentan arm,
hereas no improvement was seen with placebo (355 plus or
inus 25 m at baseline and 349 plus or minus 44 m at week
2). The median change from baseline was 51 m with
osentan versus 6 m with placebo. The mean difference
etween treatment arms in the 6MW test was 76 plus or
inus 31 m (mean plus or minus SEM) in favor of bosentan
95% confidence interval: 12 to 139; p0.021). Bosentan
mproved cardiac index and reduced mPAP and PVR.
unctional class improved in patients treated with bosentan.
A second double-blind, placebo-controlled study evalu-
ted bosentan in 213 patients with WHO functional classes
II to IV PAH (either idiopathic or associated with con-
ective tissue disease) who were randomized to placebo or
osentan 125 or 250 mg twice daily for a minimum of 16
eeks (62.5 mg twice daily for 4 weeks, then target dose)
143). The primary end point was change in exercise
apacity (assessed by 6MW test), and secondary end points
ncluded changes in Borg dyspnea index, WHO functional
lass, and time from randomization to clinical worsening.
fter 16 weeks, bosentan improved the 6MW test by 36 m,
hereas deterioration (8 m) was seen with placebo, and
he difference between treatment groups in the mean change
n 6MW test was 44 m in favor of bosentan (95% confi-
ence interval: 21 to 67 m, p0.0002). No dose response
or efficacy could be ascertained, although the placebo-
orrected improvement in 6MW test for the currently
DA-approved dose of 125 mg twice daily was 35 m. This
tudy was the first to assess time to clinical worsening, a
omposite morbidity and mortality end point. Time to
linical worsening was defined in this study as time to death,
ung transplantation, hospitalization for PH, lack of clinical
mprovement or worsening leading to discontinuation, need
or epoprostenol therapy, or atrial septostomy. The risk of
linical worsening was reduced by bosentan compared with
lacebo (p0.0015). Abnormal hepatic function (as indi-
ated by elevated levels of alanine aminotransferase and/or
spartate aminotransferase), syncope, and flushing occurred
ore frequently in the bosentan group. Abnormal hepatic
unction was dose-dependent, being more frequently re-
orted as an adverse event in the high dosage bosentan
roup (250 mg twice daily) than in the low dosage group
125 mg twice daily) (14% versus 5%, respectively).
Longer-term data regarding bosentan therapy have been
ore recently published. McLaughlin et al. (82) reported
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ddition or transition to other therapy as needed, resulted in
aplan-Meier survival estimates of 96% at 12 months and
9% at 24 months. At the end of 12 and 24 months, 85%
nd 70% of patients, respectively, remained alive and on
osentan monotherapy. Similar survival rates of 90% and
7% at 1 and 2 years were reported in a single center
etrospective analysis (144). However, based on predefined
linical criteria, 44% of patients required prostanoid therapy
uring follow up. Sitbon et al. (145) compared open label
urvival in functional class III IPAH treated with bosentan
ith historical data from similar patients treated with
poprostenol. Baseline characteristics for the 139 patients
reated with bosentan and the 346 patients treated with
poprostenol suggested that the epoprostenol cohort had
ore severe disease. Kaplan-Meier survival estimates after 1
nd 2 years were 97% and 91%, respectively, in the
osentan-treated cohort and 91% and 84% in the epopro-
tenol cohort.
Bosentan therapy has also been evaluated by Galie et al.
146) in a multicenter, double-blind, randomized, and
lacebo-controlled study in patients with functional class III
isenmenger syndrome (the BREATHE-5 [Tracleer
Bosentan) in Patients With Pulmonary Arterial Hyperten-
ion Related to Eisenmenger Physiology] study). Fifty-four
atients were randomized 2:1 to bosentan versus placebo for
6 weeks. Bosentan did not worsen oxygen saturation, and
ompared with placebo, bosentan reduced pulmonary vas-
ular resistance index, decreased mPAP, and increased
xercise capacity. Four patients discontinued due to adverse
vents, 2 (5%) in the bosentan arm and 2 (12%) in the
lacebo arm. Open label data with bosentan suggest clinical
mprovements in HIV patients with PAH, while prelimi-
ary data suggest benefits in those with inoperable CTEPH
nd early stage disease (147,148). Bosentan has also recently
een evaluated in a mildly symptomatic or functional class II
opulation (149). In this study, 168 PAH patients (IPAH,
PAH, PAH associated with connective tissue disease,
norexigen use, HIV, CHD) with a mean baseline 6MW
est of 435 m were randomized to receive bosentan or
lacebo for 26 weeks. There was a significant improvement
n one coprimary end point, change in PVR, but not the
ther, change in 6MW test. There was an improvement in
he secondary end point of time to clinical worsening. The
dverse event profile with bosentan was similar to previous
tudies.
Bosentan is currently widely used in patients with PAH.
lose follow-up over time, of both efficacy and safety, is
ncouraged. The FDA requires that liver function tests be
hecked monthly, and that the hematocrit should be
hecked every 3 months. In addition to potential hepato-
oxicity, other side effects include anemia and the develop-
ent of edema. Hormonal methods of birth control may be
ess effective with concurrent administration of bosentan,
nd barrier techniques of contraception are recommended.
his is particularly important because bosentan is poten- sially teratogenic. There is concern that the endothelin
ntagonists as a class may be capable of causing testicular
trophy and male infertility. Younger males who may
onsider conceiving should be counseled regarding this
ossibility prior to taking these drugs.
.10. Sitaxsentan
itaxsentan is more selective for the ETA receptor. In a
andomized, double-blind, placebo-controlled trial (the
TRIDE-1 [Sitaxsentan to Relieve Impaired Exercise]
rial) 178 NYHA functional class II, III, and IV patients
ith either IPAH, PAH related to connective tissue disease,
r PAH related to congenital systemic to pulmonary shunts,
ere equally randomized to receive placebo, sitaxsentan 100
g, or sitaxsentan 300 mg orally once daily. Sitaxsentan
mproved exercise capacity, as assessed by 6MW test, and
unctional class after 12 weeks of treatment. The incidence
f liver function abnormalities was more favorable for the
00 mg dose, that is, the incidence of elevated aminotrans-
erase values (greater than 3 normal), which reversed in all
ases, was 3% for the placebo group, 0% for the 100-mg
roup, and 10% for the 300-mg group. In an earlier pilot
tudy, sitaxsentan was associated with fatal hepatitis when
sed at higher doses (150). The most frequently reported
aboratory adverse event was increased international nor-
alized ratio or prothrombin time, related to sitaxsentan’s
nhibitory effect on the CYP2C9 P450 enzyme, the princi-
al hepatic enzyme involved in the metabolism of warfarin.
The STRIDE-2 study randomized 247 PAH patients
245 were treated) with IPAH or PAH associated with
onnective tissue disease or CHD to blinded placebo
n62), blinded sitaxsentan 50 mg (n62) or 100 mg
n61), or open-label bosentan (n60) (151). At week 18,
atients treated with sitaxsentan 100 mg had an increased
MW test compared with the placebo group (31.4 m,
0.03), and improved functional class (p0.04). The
lacebo-subtracted treatment effect for sitaxsentan 50 mg
as 24.2 m (p0.07) and for open-label bosentan, 29.5 m
p0.05). The incidence of elevated hepatic transaminases
greater than 3 times the upper limit of normal) was 6% for
lacebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100
g, and 11% for bosentan. Sitaxsentan is currently approved
n the European Union, Canada, and Australia, but not in
he United States.
.11. Ambrisentan
mbrisentan is a relatively selective antagonist of the ETA
eceptor. A phase 2 dose-ranging study evaluated the
fficacy and safety of 4 doses of ambrisentan in patients with
AH (152). In this double-blind study, 64 patients with
PAH or PAH associated with connective tissue disease,
norexigen use, or HIV infection were randomized to
eceive various doses of ambrisentan (1, 2.5, 5, or 10 mg)
nce daily for 12 weeks. The 6MW test (plus 36.1 m, p
0.0001) improved from baseline with ambrisentan, withimilar increases for each dose group (range plus 33.9 to plus
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ncluding the incidence of elevated serum aminotransferase
oncentrations greater than 3 times the upper limit of
ormal (incidence of 3.1%). Two pivotal phase III clinical
rials of ambrisentan in PAH have been completed and
andomized 202 and 192 patients with PAH respectively to
lacebo or ambrisentan. Doses of 5 and 10 mg of ambrisen-
an were compared with placebo in ARIES (Ambrisentan in
ulmonary Arterial Hypertension, Randomized, Double-
lind, Placebo-Controlled, Multicenter, Efficacy Study)-1,
nd doses of 2.5 and 5 mg of ambrisentan were compared
ith placebo in ARIES-2 (153). After 12 weeks, there were
mprovements in the primary end point of 6MW test in
oth studies. The change in mean 6MW test in ARIES-1
as plus 22.8 m and plus 43.6 m for the 5- and 10-mg
oses, respectively, and minus 7.8 m in the placebo group.
n ARIES-2 it was plus 22.2 m and plus 49.4 m for the 2.5-
nd 5-mg doses, respectively, and minus 10.1 m in the
lacebo group. The secondary end point of time to clinical
orsening was improved with active therapy in ARIES-2.
mbrisentan was FDA approved in June 2007 for PAH
atients with functional class II and III symptoms. As a
lass, endothelin receptor antagonists have the potential for
iver injury and teratogenicity. The incidence of transami-
ases elevations at 1 year was 2.8% in the clinical trials.
onthly monitoring of liver function tests, a monthly
regnancy test in women of child-bearing potential, and
eriodic hemoglobin measurements are required. Other
otential side effects include lower extremity edema, which
s more frequent (29%) and severe in patients over 65 years
f age, and nasal congestion (154). Precautions regarding
ontraception and testicular atrophy are similar to bosentan.
.12. Phosphodiesterase Inhibitors
s discussed in Section 3, the vasodilatory effects of NO
epend upon its ability to augment and sustain cGMP content
n vascular smooth muscle. NO activates guanylate cyclase,
hich increases cGMP production. Cyclic GMP causes va-
orelaxation, but its effects are short-lived due to the rapid
egradation of cGMP by PDEs. PDE-5 hydrolyzes cAMP
nd cGMP, limiting their intracellular signaling. PDE-5
nhibitors, such as sildenafil and tadalafil, might therefore be
xpected to enhance or prolong the effects of these vasodilating
and perhaps antiproliferative) cyclic nucleotides.
.13. Sildenafil
ildenafil is a specific PDE5 inhibitor that has been utilized
reviously for treatment of erectile dysfunction. The
UPER-1 (Sildenafil Use in Pulmonary Arterial Hyperten-
ion) study was a randomized, double-blind, placebo-
ontrolled trial that assigned 278 patients with PAH (either
PAH or PAH associated with connective tissue disease or
ith repaired congenital systemic-to-pulmonary shunts) to
lacebo or sildenafil (20, 40, or 80 mg) orally 3 times daily
or 12 weeks (155). The 6MW test increased from baseline
n all sildenafil groups, with mean placebo-corrected treat- eent effects of 45, 46, and 50 m for 20-, 40-, and 80-mg
oses of sildenafil, respectively (p0.001 for all compari-
ons). This appeared to be entirely related to improvements
ith active therapy, as there was little change in 6MW test
n the placebo group. All sildenafil doses reduced the mPAP
nd improved functional class. The incidence of clinical
orsening did not differ significantly between the patients
reated with sildenafil versus placebo. Long-term data
available only at a dose of 80 mg 3 times daily) in 222
atients completing 1 year of treatment with sildenafil
onotherapy showed sustained improvement from baseline
t 1 year in the 6MW test (51 m). The FDA-approved dose
f sildenafil in patients with PAH is 20 mg administered
rally 3 times daily. Side effects include headache, flushing,
yspepsia, and epistaxis. There has been considerable dis-
ussion as to whether or not higher doses might confer
dditional hemodynamic benefit, but such doses continue to
e “off-label” (156).
.14. Tadalafil
nother longer-acting PDE inhibitor, tadalafil, is currently
ndergoing clinical study. Like sildenafil, tadalafil has been
pproved previously by the FDA for treatment of erectile
ysfunction. However, it remains investigational in patients
ith PAH.
.15. Combination Therapy
iven the availability of medications that target different
athologic processes, combination therapy is an attractive
heoretical option in PAH, just as in LV systolic dysfunc-
ion. The goal of combination therapy should be to maxi-
ize efficacy, while minimizing toxicity. The safety and
fficacy of combination therapy in PAH is a subject of active
nvestigation. To date, there are 3 small, placebo-controlled,
ombination therapy trials. One studied functional class III
r IV patients with either IPAH or PAH related to
onnective tissue disease starting on intravenous epoproste-
ol and randomized them to receive bosentan or placebo
157). This small, underpowered study failed to demon-
trate the benefits of combination therapy. More recently,
nhaled iloprost has been studied in patients who remained
ymptomatic (NYHA functional class III or IV) while on
table bosentan therapy for at least 3 months (158). In this
ulticenter, placebo-controlled, randomized trial, 67 pa-
ients with PAH (94% NYHA functional class III, mean
aseline 6MW test 355 m) were randomized to receive
nhaled iloprost, (5 mcg, 6 to 9 times per day) or placebo.
fter 12 weeks, the primary efficacy measure, post inhala-
ion 6MW test, improved by 30 m in the iloprost group and
m in the placebo group, for a placebo-adjusted difference
f plus 26 m (p0.051). There were also improvements in
YHA functional class (p0.002), time to clinical worsen-
ng (p0.022) and postinhalation mPAP (p0.001) and
VR (p0.001). However, a study with a similar design was
erminated early due to a futility analysis (159). The primary
nd point, change in 6MW test, improved by 1 m in the
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one of the secondary end points, including functional
lass, peak oxygen uptake, and time to clinical worsening,
iffered between the groups. Most recently, the addition of
ildenafil (target dose 80 mg 3 times daily) or placebo was
valuated in 267 PAH patients who remained symptomatic
ith a 6MW test of 100 to 450 m while on a stable dose of
ntravenous epoprostenol for at least 3 months (160).
atients treated with sildenafil experienced a placebo-
djusted improvement in 6MW test of 28.8 m (p0.0002)
t 16 weeks, as well as improvements in mPAP, cardiac
utput, and time to clinical worsening. Several smaller, open
abel observational studies have suggested benefit of com-
ination therapy. Multiple randomized controlled trials of
ombination therapy are currently ongoing, and to ade-
uately study the safety and efficacy of combination therapy,
e encourage enrollment into randomized controlled trials.
.16. Limitations of Clinical Trials in
ulmonary Arterial Hypertension
hile the medications studied in the clinical trials reviewed in
he preceding text represent, in our view, advancements in the
are of PAH patients, many patients still remain symptomatic,
ith a suboptimal quality of life and impaired hemodynamics
espite treatment. With the exception of calcium channel
lockers in a robust responder, most therapies reduce PAP by
0% to 20%. A recent meta-analysis of 16 randomized trials in
AH found the following: 1) a nonsignificant reduction in
ll-cause mortality (relative risk 0.70, 95% confidence interval:
.41 to 1.22); 2) a significant improvement in exercise capacity
s assessed by the 6MW test of 42.6 m (95% confidence
nterval: 27.8 to 57.8 m); and 3) an improved dyspnea status by
t least 1 functional class (relative risk 1.83, 95% confidence
nterval: 1.26 to 2.66) (161). Notably, with one exception,
hese trials were all 8 to 16 weeks in duration. None were
owered to detect a survival benefit. More recently, a meta-
nalysis performed on 21 randomized controlled trials (3140
atients) in PAH patients published through October 2008
eported improvements in the 6MW distance and a 43%
ecrease in mortality in patients treated with PAH-specific
herapies versus patients randomized to placebo (161a). Addi-
ionally, the role of PAH-specific therapy in certain subgroups
as not been adequately studied. For example, a meta-analysis
f the scleroderma spectrum of diseases related PAH patients
ncluded in 10 randomized controlled trials of oral therapy failed
o demonstrate an improvement in exercise capacity in this
ubgroup (162). Interestingly, this is contrary to the study of
poprostenol performed specifically in the scleroderma spectrum
f diseases population, which demonstrated the greatest improve-
ent in 6MW test ever reported in a clinical trial in PAH (117).
.17. Cost Considerations
linical trials in PAH have not included analysis regarding
ost/benefit ratio, quality-adjusted life years saved, or num-
er needed to treat. The PAH-specific therapies are expen-
ive. The approximate annual cost for sildenafil is $12 761, dor bosentan is $55 890, for ambrisentan is $56 736, and for
loprost is $92 146. Because dosing is individualized and a
atient’s weight factors into the amount of drug used, there
s considerable variation in the cost of epoprostenol and
reprostinil from patient to patient. Based on a 70-kg
atient at the lower end of the dosing spectrum, the annual
ost for epoprostenol is $33 153 and for treprostinil is
97 615. These costs may be much higher for larger patients
nd at higher doses (163).
.18. Invasive Therapies
espite advances in the medical treatment for PAH, many
atients experience progressive functional decline, largely
elated to worsening right heart failure. It is in these patients
hat interventional and surgical therapeutic options should
e considered, including atrial septostomy and lung or
ombined heart and lung transplantation. In patients with
H caused by chronic pulmonary thromboembolism, sur-
ical thromboendarterectomy may be beneficial. A body of
linical data has emerged to help guide the utilization of
hese strategies, and reviews of their role in the therapy of
atients with PAH have recently been published (164–166).
ther surgical approaches, such as RV mechanical assis-
ance, are under investigation.
.19. Atrial Septostomy
s right heart function worsens in response to ongoing
evere PAH, patients experience progressive dyspnea, as-
ites, edema, and may have presyncope or syncope. Atrial
eptostomy creates a right to left inter-atrial shunt, decreas-
ng right heart filling pressures and improving right heart
unction and left heart filling. While the created shunt
ecreases systemic arterial oxygen saturation, it is antici-
ated that the improved cardiac output will result in overall
ugmentation of systemic oxygen delivery.
Several case series have reported hemodynamic and clin-
cal improvement following the procedure (167–169). Im-
roved cardiac output appears to be the principal hemody-
amic benefit; the magnitude of the improvement has
anged from 15% to nearly 60%. Improvements in NYHA
unctional class and 6MW test have also been reported
169). Reported success rates for bridging patients to trans-
lantation with septostomy range from 30% to 40%
167,168). Procedural mortality is high, however, with an
stimate of 15% based on published series (though this has
anged from 5% to 50% in the different centers). This mortality
s undoubtedly driven by the severity of PAH and right heart
ailure of the patients undergoing the procedure. At the same
ime, however, this mortality clearly contributes to the practice
f reserving the procedure for critically ill patients. Within this
roup, those with advanced age, renal dysfunction, and the
ost severe derangements in hemodynamics and systemic
xygenation face the greatest procedural risk.
Atrial septostomy may be performed by either blade or
raded balloon dilation techniques, both of which have been
escribed previously. Recently, the utility of a customized
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ardiographic imaging to guide the location and extent of
eptostomy creation (171) have been reported. Ongoing
dvances may yield improved outcomes in the future.
Currently, atrial septostomy is recommended for patients
ith severe PAH and intractable right heart failure despite
aximal medical therapy, including optimized PAH-specific
gents and inotropes. Indeed, this represents a very narrow
indow and identification of appropriate patients requires
xperience and judgment. The goals of the procedure are
alliation and restoration and maintenance of clinical stability
ntil a transplant can be performed. Atrial septostomy should
e performed only by experienced operators in centers with the
esources to care for such critically ill patients. The procedure
hould be considered before hemodynamic compromise and
nd-organ dysfunction is too far advanced.
.20. Lung and Combined Heart and
ung Transplantation
ung transplantation has been an option for the therapy for
elect patients with end-stage pulmonary disease for the past
5 years. Currently, approximately 4% of the approximately
,700 single lung (SLTx), double lung (DLTx), and com-
ined heart and lung (HLTx) transplants annually per-
ormed worldwide in adults are for the primary indication of
AH (172). While patients with PAH undergoing trans-
lantation face an increase in operative mortality, their long
erm outcomes are comparable with patients with other
rimary indications (172). The International Society for
eart and Lung Transplant registry reports 1-, 3-, 5-, and
0-year survivals of 66%, 57%, 47%, and 27%, respectively,
n PAH patients undergoing transplant. By way of compar-
son, survival rates for all patients transplanted were 78%,
1%, 49%, and 25% at these respective time points (172,173).
There is no agreement on the optimal type of transplan-
ation for patients with PAH. While acceptable outcomes
ave been demonstrated with SLTx, many centers prefer
LTx to limit the reperfusion injury that has been reported
n the donor lung of PAH patients undergoing SLTx (174).
he decision to perform HLTx in PAH patients is based on
he severity of cardiac decompensation. The combined
rocedure is generally reserved for patients with intractable
ight heart failure, especially when a patient has become
ependent on inotropic support. Combined heart and lung
ransplant is also often required in patients with PAH in the
etting of complex CHD, although in some instances
ombining SLTx or DLTx with simultaneous repair of the
ongenital cardiac abnormality may be feasible (175). Also,
atients with PH and concomitant advanced left heart
isease may be considered for HLTx. Finally, when PAH is
ot the primary indication for lung transplantation, the pres-
nce of secondary PH and its sequelae may similarly impact the
hoice of transplant type. Choice of procedure is therefore
ependent on the patient characteristics, as well as the desire to
ptimally use scarce donor organs, the ease (or difficulty) of
ach surgical procedure, and a given center’s preference. iTransplantation as a potential therapeutic option should be
iscussed with PAH patients at the time of diagnosis. Timing
f referral is challenging, and local practices and organ avail-
bility must be considered. Patients who are otherwise good
ransplant candidates should be referred when they have an
nacceptable response to PAH therapies. In the current patient
rioritization scheme used by the United Network for Organ
haring, patients with PAH may be assigned a lung allocation
core below that of patients with other common diagnoses,
uch as pulmonary fibrosis. In addition, a determination that a
atient is functional class IV paradoxically lowers the patient’s
core (a recognition of the worsened peri- and posttransplant
utcomes observed in these patients). The thoracic committee
f the United Network for Organ Sharing is constantly
eviewing and revising this process. Application for an excep-
ion based on certain hemodynamic criteria is now possible for
AH patients. Revisions to the scoring system to include
hanges in bilirubin and creatinine are being discussed. Once a
atient has been evaluated and considered a candidate for
ransplantation, aggressive follow up and therapy are required
o maintain cardiac function and improve the likelihood that a
ombined heart and lung transplant will not be required.
.21. Pulmonary Thromboendarterectomy
atients with suspected PAH should undergo evaluation for
TEPH. As discussed in the preceding text, the screening
ool of choice for CTEPH is perfusion scanning. If indic-
tive of CTEPH, a pulmonary angiogram should be per-
ormed. Patients are considered to be candidates for pulmo-
ary thromboendarterectomy (PTE) if they have surgically
ccessible disease and present acceptable surgical risk. The
oal of PTE is to remove sufficient material from the
ulmonary arteries to substantially lower PVR and improve
ardiac output. The diagnostic evaluation of patients with
TEPH, surgical technique, and outcomes have been
eviewed recently (104). This complex and life-saving therapy
s best performed at high-volume centers as the learning curve
nd required support systems are prohibitive for most hospitals.
.22. Right Ventricular Assist Device
he development of refractory right heart failure portends a
rave prognosis in patients with PAH. Left- and biventricu-
ar assist devices have proven effective in supporting patients
ith severe left- and biventricular failure. Preclinical studies
ave suggested the usefulness of right ventricular assist
evice (RVAD) support in a model of PH (176). While a
rowing body of literature has emerged demonstrating the
tility of RVAD support in patients with acute postopera-
ive RV failure, often in the presence of PH, its utility in
atients with PAH has not as yet been tested.
.23. Treatment Algorithm
he optimal therapy for a patient is a highly individualized
ecision, taking into account many factors including: sever-
ty of illness, route of administration, side effects, comorbid
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ithm for therapy of PAH is depicted in Figure 6 (99).
. Reassessing Patients Over Time:
ow to Follow Patients on Treatment
hile guidelines for the diagnosis and initial treatment have
een developed recently, a guideline focusing on how to
eassess patients over time has been lacking. Almost all of the
andomized clinical trials studying PAH therapies to date have
een short-term studies, usually 12 to 16 weeks in duration.
urthermore, the long-term experiences published thus far
sually detail single center experiences, without placebo or
ontrol groups, making it difficult to infer generalized practice
atterns. Most importantly, treatment of PAH is a rapidly
volving field with emergence of new information and devel-
pment of novel therapies, which have further hampered
igure 6. Treatment Algorithm for PAH
ackground therapies include warfarin anticoagulation, which is recommended in all
eart failure. Oxygen is recommended to maintain oxygen saturation greater than 90
otential candidates for long-term therapy with calcium channel blockers (CCBs). Pat
esponsiveness to oral CCBs, and the value of acute vasodilator testing in such pati
red, such as those with right heart failure or hemodynamic instability, should not u
ive acute vasodilator response, and such patients need to be followed closely both
esting and are considered lower risk based on clinical assessment (Table 2), oral th
en is not appropriate, the other treatments would need to be considered based on
red high risk based on clinical assessment (Table 2), continuous treatment with int
ecommended. If a patient is not a candidate for continuous IV treatment, the other
isk of each treatment. Epoprostenol improves exercise capacity, hemodynamics, an
lthough expensive and difficult to administer, epoprostenol is the only therapy for P
inuous IV or subcutaneous (SC) infusion. Iloprost is a prostacyclin analogue delivere
re oral therapies that improve exercise capacity in PAH. Liver function tests must b
xercise capacity. Combination therapy should be considered when patients are not
nd/or atrial septostomy is challenging and is reserved for patients who progress dereation of a coherent guideline outlining ongoing evaluation. pThe complexity of the disease and the rapid advances
ccurring in PAH mandate a guideline outlining long-term
anagement recommendations. Although the therapies
hat have been approved thus far have been effective in
mproving quality of life and outcome to varying degree,
linical experience has demonstrated that some patients
rogress despite treatment while others decline after initial
mprovement. Furthermore, long-term experiences with
poprostenol have demonstrated the importance of vigilant
arly follow-up, since patients who remain in functional
lass III or IV despite therapy have poor outcomes and
hould be considered for lung transplant (77,78).
Important prognostic indicators, both at baseline and on
reatment, were reviewed in Section 5 of this document.
hese include WHO functional class, exercise endurance
6MW test or CPET), and echocardiographic and hemo-
ynamic parameters. There are emerging data regarding the
ts with IPAH without contraindication. Diuretics are used for management of right
cute vasodilator testing should be performed in all IPAH patients who may be
with PAH due to conditions other than IPAH have a very low rate of long-term
eeds to be individualized. IPAH patients in whom CCB therapy would not be consid-
acute vasodilator testing. †CCBs are indicated only for patients who have a posi-
fety and efficacy. ‡For patients who did not have a positive acute vasodilator
with ERA or PDE-5I would be the first line of therapy recommended. If an oral regi-
nt’s profile and side effects and risk of each therapy. §For patients who are consid-
us (IV) prostacyclin (epoprostenol or treprostinil) would be the first line of therapy
ies would have to be considered based on patient’s profile and side effects and
ival in IPAH and is the preferred treatment option for the most critically ill patients.
t has been shown to prolong survival. Treprostinil may be delivered via either con-
n adaptive aerosolized device 6 times daily. The endothelin receptor antagonists
itored indefinitely on a monthly basis. Phosphodiesterase inhibitors also improve
ding adequately to initial monotherapy (Table 8). Timing for lung transplantation
optimal medical treatment.patien
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f the PAH patient are displayed in Table 8.
Combining agents of different classes for the treatment of
AH patients who remain symptomatic and do not achieve
reatment goals is an area of active research. Limited data
rom randomized controlled trials suggest that outcomes are
etter when multiple agents are used in such patients, and
arger randomized controlled trials to address this issue are
nderway. Addition of an endothelin receptor antagonist,
DE-5 inhibitor, or a prostanoid could also be considered
utside of a trial setting. If a patient improves with the
dditional agent, it is unclear whether the initial agent
hould be continued or discontinued.
.1. Role of Nurses in Managing Pulmonary Arterial
ypertension Patients at Specialty Centers
t is our opinion that nurses provide a crucial link between
he physician(s) and patient in all PAH specialty centers.
irst, competent nursing education of the patient, triage,
nd medical assessment are necessary to manage PAH
atients who not only have complex disease but also need
omplex therapies, such as intravenous or subcutaneous
rostanoids. Frequent telephone calls are necessary during
nitiation, after an episode of decompensation, and for
eriodic evaluation with these treatments. It is also crucial
or patients to be proactive in the management of their
isease and to be instructed to communicate with the nurses
n the event of clinical problems. This is best accomplished
hen patients are given specific instructions, access to the
ursing staff, and a shared sense of responsibility for
anaging their disease and treatment plan.
Nurses also provide emotional support to patients and
heir families, especially during the initial period of
able 8. Longitudinal Evaluation of the PAH Patient*
linical Course Stable; no increase in symptoms and/or de
hysical Examination No evidence of right heart failure
unctional Class I/II
MWD Greater than 400 m
chocardiogram RV size/function normal
emodynamics RAP normal
CI normal
NP Near normal/remaining stable or decreasin
reatment Oral therapy
requency of Evaluation Q 3 to 6 months‡
C Assessment Every clinic visit
MWT Every clinic visit
chocardiogram§ Q 12 months or center dependent
NP Center dependent
HC Clinical deterioration and center dependen
For patients in the high-risk category, consider referral to a PH specialty center for considera
valuation for patients in FC III and/or 6MWD between 300 to 400 m would depend on composite
table on established therapy, follow-up assessments can be performed by referring physician(s)
dvised not to rely on its evaluation as the sole parameter to make therapeutic decisions. The
BNP indicates brain natriuretic peptide; CI, cardiac index; FC, functional class; MWD, molecula
trial pressure; RHC, right heart catheterization; and RV, right ventricle.ccepting the diagnosis or with acute illness. They spend Iime educating patients on the disease process and
nswering questions regarding different therapies or is-
ues on how PAH impacts activities of daily living. Also,
urses are often the ones patients and their families turn
o for assistance for help in navigating through insurance
ompanies and dealing with realities associated with
nancial aspects of PAH therapies. Indeed, one of the
istinguishing features that marks a group as a PAH
pecialty center is the availability of competent and caring
ursing staff dedicated to meeting the unique challenges
f patients with PAH (Table 9). Additionally, specialty
harmacies that dispense many of the PAH therapies
mploy nurses and pharmacists who play a key role in
ducating patients about the therapies.
. Non-Pulmonary Arterial Hypertension
ulmonary Hypertension Populations
hile recent evidence points to an increase in the number
f patients with WHO Group 1 PAH (1), the number of
ensation Unstable; increase in symptoms and/or decompensation
Signs of right heart failure
IV†
Less than 300 m
RV enlargement/dysfunction
RAP high
CI low
Elevated/increasing
Intravenous prostacyclin and/or combination treatment
Q 1 to 3 months
Every clinic visit
Every clinic visit
Q 6 to 12 months or center dependent
Center dependent
Q 6 to 12 months or clinical deterioration
r advanced therapies, clinical trials, and/or lung transplantation. †The frequency of follow-up
iled assessments on other clinical and objective characteristics listed. ‡For patients who remain
pecialty centers. §Echocardiographic measurement of PASP is estimation only and it is strongly
of serial BNP levels to guide management in individual patients has not been established.
t distribution; MWT, minute walk test; PAH, pulmonary arterial hypertension; Q, every; RAP, right
able 9. The Role of Nurses in Managing PAH Patients at
pecialty Centers
Clinical Indication Frequency of Phone Triage/Management
fter initiation of IV
prostacyclin
1 to 2/week to weekly until dose titration/
symptoms stable
hronic IV prostacyclin Q 1 to 2 months and prn
fter initiation of combination
therapy
Q 2 to 4 weeks and/or prn
fter initiation of oral regimen Q 1 to 2 months and/or prn
fter discharge from hospital
for PAH decompensation
Q days to 1 week for 1 to 2 weekscomp
g
t
tion fo
of deta
or PH s
utilityV indicates intravenous; PAH, pulmonary arterial hypertension; prn, as needed; and Q, every.
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619atients with PH related to chronic left heart disease
WHO Group 2) or chronic hypoxic states (WHO Group
) is far greater. It is universally agreed that such patients
equire optimization of therapies targeting their underlying
isease state (tailored heart failure interventions for patients
ith congestive heart failure, for example). However, it is
ot uncommon that even with such optimization, clinically
eaningful PH remains. A subset of patients may be
escribed as having PH “out of proportion” to their under-
ying disease state. Examples would include patients with a
odest degree of obstructive lung disease or left heart
isease that nonetheless manifest severe PH. Some have
peculated that these patients have a form of PAH that may
erit therapy with PAH-specific agents. Unfortunately,
here are relatively few data available to guide decision
aking regarding the use of PAH-specific therapies for
hese patients. Other populations in which the use of these
herapies is controversial include those with CTEPH and
hose with PH following a variety of cardiac surgical
rocedures. This section explores the diagnostic and thera-
eutic approach to these patient populations.
.1. WHO Group 2: Pulmonary Venous Hypertension
.1.1. Systolic Heart Failure and Pulmonary Hypertension
espite significant advances in the treatment of patients
ith systolic heart failure with neurohormonal modulators
ncluding angiotensin-converting enzyme inhibitors, beta-
lockers, and spironolactone, the morbidity and mortality
mong patients with advanced heart failure remains high
177). Development of PH, which usually progresses to
ffect RV function, signals progression of disease and poor
utcome (5). PH in association with left heart failure usually
ccurs initially as pulmonary venous hypertension. Over a
eriod of time, partly as an adaptive mechanism against
ulmonary edema, an increase in pulmonary artery resis-
ance may ensue.
Although optimizing neurohormonal antagonists re-
ains the mainstay in treating patients with systolic heart
ailure, efforts to target PAH by applying similar principles
sed in treating idiopathic PAH have been pursued. The
IRST (Flolan International Randomized Survival Trial)
tudy enrolled 471 patients with advanced heart failure to
eceive continuous epoprostenol infusion plus standard care
r standard care alone (178). Although a hemodynamic
mprovement was seen among patients receiving epoproste-
ol with an increase in CI and a decrease in PCWP and
VR, the study was terminated early due to a strong trend
oward increased mortality rates in patients receiving
poprostenol. Several explanations given included the long-
erm detrimental effects observed with systemic vasodilata-
ion in systolic heart failure and possible hazardous effects of
poprostenol among patients with ischemia. Based on the
ndings of this study, chronic use of epoprostenol in
atients with systolic heart failure is contraindicated. The
nly other prostanoid-based agent tested in patients with shronic heart failure is inhaled iloprost (179). Investigators
ave reported hemodynamic benefits of short-term use of
loprost in heart transplant candidates with increased PAP.
ignificant decreases in mPAP and PVR was demonstrated.
Similar to increase in activation of several other neuro-
ormonal systems, the level of endothelin (ET)-1 is also
ncreased in chronic heart failure (180). Studies investigat-
ng the short-term hemodynamic effect of endothelin re-
eptor antagonists (ERAs) in patients with chronic heart
ailure were initially encouraging. A 2-week therapy with
onselective ERA bosentan in 36 patients with symptom-
tic heart failure despite treatment with standard regimen
esulted in a reduction of both systemic and pulmonary
ressures and increase in cardiac output (181). These initial
ncouraging results prompted long-term randomized trials.
n the REACH-1 (Research on Endothelin Antagonists in
hronic Heart Failure) study, 370 patients with advanced
eart failure (NYHA functional class IIIB/IV) received
osentan or placebo. However, this trial was stopped pre-
aturely due to safety issues, namely elevated liver
ransaminases, and the question of possible long-term
enefit using lower doses was raised based on observing a
rend towards reduction in heart failure-related morbidity
nd mortality among patients who received therapy (182).
he ENABLE (Endothelin Antagonist Bosentan for Low-
ring Cardiac Events in Heart Failure) trial enrolled over
600 patients and studied lowered doses of bosentan versus
lacebo (183). However, no improvement in outcome was
emonstrated between patients treated with bosentan and
onventional treatment versus conventional treatment alone.
here was an increased risk of early heart failure exacerba-
ions due to fluid retention in patients treated with bosentan.
Several hypotheses have been raised regarding the lack of
mprovement seen with the addition of ERAs in heart
ailure patients. One reason may lie in patient selection.
ndothelin receptor blockers reduce PAP and increase
ardiac output in patients with IPAH (142). It is possible
hat adding ERAs may prove to be beneficial only for
atients with chronic heart failure and PH. Indeed, a recent
eport described 5 patients who were deemed ineligible for
eart transplantation due to severe irreversible PH (184). A
-week trial of bosentan resulted in decreased PVR, making
he patients eligible for heart transplantation, which they all
nderwent successfully. Another case report illustrates a
atient who was considered for heart and lung transplanta-
ion secondary to biventricular dysfunction and severe PH
185). After 3 months of therapy on bosentan, improvement
n LV function and PAP made him eligible for double lung
ransplantation. Larger studies are needed to determine the
afety and benefit of adding ERAs to currently used
eurohormonal antagonists among patients with chronic
eart failure and PH.
Two small reports have demonstrated safety and hemo-
ynamic effects of short-term use of sildenafil in patients
ith congestive heart failure and PH (186,187). An acutetudy has shown that sildenafil administration improved
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ary vasodilatation during rest and exercise in patients with
eart failure and PH (188). In addition, sildenafil treatment
or 12 weeks improved exercise capacity and quality of life in
atients with systolic heart failure and PH, compared with
lacebo-treated patients (189). Longer-term use of PDE-5
nhibitors in heart failure patients has not been investigated
o date.
.1.2. Diastolic Heart Failure and Pulmonary Hypertension
iastolic heart failure refers to clinical syndromes in which
atients present with heart failure symptoms with preserved
V systolic function. The predominant underlying struc-
ural abnormalities in diastolic heart failure are concentric
ypertrophy and/or remodeling. This is often caused by
hronic pressure overload, usually due to hypertension. The
ther characteristics associated include normal or reduced
V volume, abnormal diastolic function, and left atrial
nlargement (190). These abnormalities impair the filling
rocess of the left ventricle, especially under conditions that
ncrease the heart rate (i.e., exercise or arrhythmia), resulting in
nadequate cardiac performance and clinical symptoms.
Treatment strategies for diastolic heart failure include
reating hypertension and preventing or aiming for regres-
ion of hypertrophy, accomplished mainly by using
ngiotensin-converting enzyme inhibitors and angiotensin
eceptor blockers. Strict volume control is necessary, ob-
ained through diuretics and sodium restriction. Prevention
f tachyarrhythmia and controlling the heart rate to opti-
ize diastolic filling time are most often achieved using
eta-blockers and calcium channel blockers. Furthermore,
mproving lusitropy and preventing ischemia are also im-
erative when considering treatment strategy.
There are no established guidelines for treatment of
iastolic heart failure. Many patients with this syndrome
hare similar risk profiles such as hypertension, diabetes
ellitus, LV hypertrophy, atrial fibrillation, sleep disordered
reathing (SDB), and atherosclerotic disease. Therefore,
ome of the general principles used in treating systolic heart
ailure patients have been applied. A few small studies have
hown that angiotensin receptor blockers improve exercise
olerance. The CHARM (Candesartan in Heart failure:
ssessment of Reduction in Mortality and morbidity)-
reserved trial suggested that treatment with candesartan
educes hospitalization related to diastolic heart failure,
hough mortality benefit was not seen (191).
When patients present with both diastolic heart failure
nd elevated PAP, measures to optimally treat systemic
ypertension and normalize volume status must be in place.
erforming RHC with careful attention paid to obtaining
ccurate PCWP, and in most cases LVEDP, is important in
lacing the correct diagnosis. Paradoxically, it is possible
hat the PCWP or LVEDP might be normal in such a
atient with severe RV failure and low cardiac output. If
AP remains elevated despite normalizing systemic blood
ressure and attaining euvolemic status, it is unclear if honsideration should be given to targeted therapy for PAH.
urthermore, in the presence of hypertrophy and/or echo-
ardiographic evidence of abnormal relaxation, it is un-
nown what PAP should be considered “out of proportion”
o the presence of left heart changes. No studies are available
o guide this therapeutic decision.
.1.3. Valvular Dysfunction and Pulmonary Hypertension
evelopment of PH in association with valvular dysfunction
as been shown to be a marker of advanced disease.
osenhek et al. (192) reported their findings from prospec-
ively following 132 consecutive patients with severe degen-
rative mitral regurgitation for 62 plus or minus 26 months.
his group used criteria consisting of development of
ymptoms, LV enlargement or dysfunction, recurrent atrial
brillation, or PH. Evaluation of event-free survival dem-
nstrated the presence of symptoms to be correlated with
orst outcome; however, among this cohort, only 5 patients
eveloped new onset of atrial fibrillation or PH. This study
s in accordance with the U.S. and European practice
uidelines recommendation for surgery in asymptomatic
atients with MR with regards to presence of PH. The
uideline recommends systolic PAP exceeding 50 mm Hg
o be a IIa indication for surgery (193).
Elevated estimated RV systolic pressure on echocardiog-
aphy has multiple potential etiologies. When an etiology
uch as left heart disease or pulmonary disease is found, the
nderlying disorder should be treated aggressively. In many
nstances the PAP will decline with appropriate manage-
ent of the underlying disorder. If the estimated PAP
emains elevated, and the patient remains symptomatic,
urther evaluation, including an RHC, may be appropriate.
.2. WHO Group 3: Hypoxia-Associated
ulmonary Hypertension
he respiratory diseases most frequently associated with PH
re chronic obstructive pulmonary disease, interstitial lung
isease, and SDB. Less common pulmonary abnormalities,
uch as chronic hypoventilation syndromes and high alti-
ude exposure, can also produce PH, but will not be
iscussed here. These are categorized as WHO Group III
H. The topic of pulmonary diseases and the heart has
ecently been reviewed (194).
.2.1. Chronic Obstructive Pulmonary Disease and
ulmonary Hypertension
hronic obstructive pulmonary disease (COPD) is a highly
revalent lung disorder of the lung parenchyma, including
irways, resulting in a ventilatory limitation to exertion,
ecurring respiratory infections, and often chronic hypoxia
nd hypercapnea. COPD, predominantly caused by smok-
ng, is associated with pulmonary vascular changes including
ntimal thickening, which decreases luminal cross-sectional
rea (195,196). While PH is thought to be common in
atients with COPD, its exact prevalence is uncertain and is
eavily influenced by disease severity: two thirds of patients
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619ith advanced COPD have been reported to have PH
etected echocardiographically (197). More recently, the
ardiopulmonary hemodynamics of a retrospective series of
98 patients with COPD has been published (198).
wenty-seven patients (3%) had severe PH, defined as an
PAP greater than 40 mm Hg. Interestingly, 16 of these 27
ad another possible cause of PH, such as anorexigen
xposure, connective tissue disease, thromboembolic dis-
ase, or LV disease. In only 11 patients, or 1.1%, was
OPD the only potential etiology of the PH. The median
AP in these 11 patients was 48 mm Hg. These patients
ad an unusual pattern of cardiopulmonary abnormalities
ith mild to moderate airway obstruction, severe hypox-
mia, hypocapnea, and a very low diffusing capacity for
arbon monoxide.
In a similar series, among 215 patients with severe
OPD who underwent RHC to evaluate candidacy for
ither lung transplantation or lung volume reduction sur-
ery, PH, defined as an mPAP greater than 25 mm Hg, was
resent in 50.2% of patients (199). The PH was character-
zed as moderate (mPAP 35 to 45 mm Hg) in 9.8% and
evere (mPAP greater than 45 mm Hg) in 3.7%. A cluster
nalysis identified a subgroup of atypical patients character-
zed by moderate impairment of the pulmonary mechanics
ith moderate to severe PH and severe hypoxemia. Obser-
ations suggest that a different biological mechanism results
n changes in the pulmonary vascular bed in susceptible
atients and that severe PH occurs in the presence of lung
isease rather than as a result of the lung disease. For
xample, a genetic predisposition to PH in COPD patients,
s a result of a 5-HTT polymorphism, has been described,
hich may predispose to more severe PH in hypoxemic
atients with COPD (200).
In the vast majority of COPD patients, PH is mild and
reatment should be directed at the underlying COPD. This
hould include bronchodilator and anti-inflammatory ther-
py, and most importantly, oxygen. Patients who present
ith severe PH should be evaluated for another disease
rocess that is responsible for the high PAP before it is
ttributed to the COPD. Specific treatment of PH in the
etting of COPD has not been adequately studied. Open
abel, uncontrolled observations with both bosentan and
ildenafil have suggested benefit, although adequately de-
igned trials are lacking (201–203). Worsening V/Q mis-
atch, resulting in further hypoxemia due to nonselective
asodilatation is a potential risk.
.2.2. Interstitial LungDisease and Pulmonary Hypertension
nterstitial lung disease (ILD) is a heterogeneous group of
isorders generally featuring inflammatory and/or fibrotic
estruction of the pulmonary parenchyma, and commonly
ssociated with PH (204). Idiopathic pulmonary fibrosis
IPF) is a relatively common form of ILD. The prevalence
f PH as determined by echocardiogram in patients with
PF is uncertain, but has been reported to be as high as 40%
n a general IPF population (205) and 60% in patients with oPF referred for lung transplant evaluation (206). As with
OPD, the magnitude of PH in patients with IPF is often
odest, though a sizeable minority may have more marked
ressure (207). Recent data have shown a lack of correlation
etween lung function variables and PAP in patients with
PF, suggesting mechanisms other than the degree of
brosis underlying the PH seen in this disease (205). The
reatment of PH associated with ILD should begin with
ptimal treatment of the ILD, potentially including immu-
omodulatory therapies and supplemental oxygen. The role
f PAH-specific therapies in the treatment of PH associated
ith ILD has not been adequately investigated.
Sarcoidosis is a disease of unknown etiology, often
rouped among the ILDs and commonly associated with
H. According to the 2003 classification, PH associated
ith sarcoidosis falls into Group V or “miscellaneous” PH.
s in COPD, the frequency with which PH complicates
arcoidosis appears to increase with disease severity (208). A
mall, uncontrolled study reported clinical improvement in
atients with severe PH associated with sarcoidosis treated
hronically with intravenous epoprostenol (209). A con-
rolled trial of bosentan in this population is scheduled to
egin in the near future.
.2.3. Sleep Disordered Breathing
DB, especially when accompanied by frequent and severe
ypoxemia, can produce PH. Generally, the magnitude of
he pressure elevation is modest even in severe cases of sleep
pnea. Accordingly, if a patient with SDB is found to have
evere PH, a complete diagnostic evaluation should be
ndertaken to assess for other possible etiologies of the PH.
t the same time, all patients with PH should be evaluated
nd treated (if indicated) for SDB to limit the adverse
ulmonary vascular effects of the SDB (210).
Therapy of PH associated with SDB centers on preven-
ion of episodic hypoxia by the provision of continuous
ositive airway pressure (with or without supplemental
xygen) or, less commonly, with surgery or the use of an oral
rosthesis. PAH-specific agents have not been studied in
atients with PH associated with SDB, although they may be
sed when PH persists despite adequate therapy of the SDB.
.3. WHO Group 4: Thromboembolic
ulmonary Hypertension
TEPH is defined as PH associated with an elevated
PAP (greater than 25 mm Hg) caused by thromboemboli
n the pulmonary arterial system. A recent prospective,
ongitudinal study following patients presenting with acute
E but with no other history of venous thromboembolism
stimated the cumulative incidence of CTEPH to be 1.0%
months after acute PE, 3.1% after 1 year, and 3.8% after
years (103), suggesting that the disease may be much more
ommon than previously believed. Hoeper et al. (104) have
ecently reviewed CTEPH in detail. The current model of
TEPH pathogenesis is based upon gradual formation of
rganized thromboemboli after deep venous thrombosis and
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athway or of the pulmonary endothelium has been consis-
ently identified except for anticardiolipin antibody (approx-
mately 10% of patients) and elevated levels of factor VIII.
plenectomy, ventriculo-atrial shunt, infected intravenous
ines, and chronic inflammatory states appear to be inde-
endent risk factors for CTEPH (212).
Pulmonary microvascular changes manifesting as pulmo-
ary hypertensive arteriopathy likely contribute to disease
rogression (211). Mechanisms for significant distal disease
ay involve: 1) obstructions of “small” subsegmental elastic
ulmonary arteries; 2) classic pulmonary arteriopathy of
mall muscular arteries and arterioles distal to nonob-
tructed vessels; and 3) pulmonary arteriopathy of small
uscular arteries and arterioles distal to totally or partially
bstructed vessels. Distal pulmonary vasculopathy of both
ccluded and nonoccluded pulmonary vasculature is char-
cterized by lesions considered typical for IPAH, including
lexiform lesions.
CT findings of CTEPH may be minimal and a
entilation-perfusion scan should always be considered in
he setting of possible CTEPH. A normal perfusion study
r the presence of multiple, small, subsegmental defects
ake IPAH or another form of small-vessel PH more
ikely, and one or more mismatched segmental or larger
efects generally indicates CTEPH. Occasionally, multiple
ismatched defects are seen in pulmonary veno-occlusive
isease, pulmonary capillary hemangiomatosis, fibrosing
ediastinitis, pulmonary vasculitis, or pulmonary artery
arcoma. CT or angiographic evidence of CTEPH includes
ouching, webs, or bands with or without poststenotic
ilatation, intimal irregularities, abrupt narrowing, or total
cclusion. Pulmonary angiography has been the cornerstone
f managing patients with CTEPH for many years and
onfirms the diagnosis and gives an indication of operability.
.3.1. Surgical and Invasive Therapy
TE is potentially curative, although it cannot be performed
n a substantial proportion of patients (104,165,213,214)
nd surgical success is dependent on careful patient selection
nd operator experience. Invasive therapeutic approaches
ther than PTE are currently limited. Possible alternatives
nclude lung transplantation and balloon pulmonary dilation
angioplasty) (164,215). The latter technique may be ben-
ficial, but it is not, at present, routinely applied (215).
hile there are little clinical data to support the practice,
nferior vena cava filter placement prior to PTE is standard
t most large centers.
.3.2. Medical Therapy
s in PAH, diuretics and oxygen are used as indicated.
ifelong anticoagulation therapy is prescribed. Pharmaco-
ogic therapies approved for use in treating IPAH are being
tudied in CTEPH in view of the potential for nonocclusive
mall vessel vasculopathy. Most clinical evidence is currently
imited to small, uncontrolled trials. There has been 1 ilacebo-controlled trial for CTEPH, which evaluated
osentan in patients with either inoperable disease or
ersistent PH following PTE (147). Patients treated with
osentan demonstrated a reduction in PVR, but no change
n 6MW test, compared with placebo.
Pharmacotherapy may be beneficial in 4 settings (216).
irst, when PTE is not possible due to significant distal
isease, medical therapy may be the only possibility, with
ransplant considered for the most severely ill individuals.
econd, in high-risk patients with extremely poor hemody-
amics, intravenous epoprostenol may be considered as a
herapeutic bridge to PTE (217). Such individuals include
hose with functional class IV symptoms, mPAP greater
han 50 mm Hg, CI less than 2.0 L/min/m2, and PVR
reater than 1,000 dyn·s·cm5 (216). While this approach
ay improve surgical success, medical therapy should not
ignificantly delay PTE. Third, patients with persistent PH
fter PTE (about 10% to 15%), and who often have
ignificant residual distal pathology, should be considered
or medical therapy. Finally, when surgery is contraindicated
ue to significant comorbidity, medical therapy can be
onsidered. Data from open label observations of medical
herapy in CTEPH have been recently reviewed and are
romising but do not permit derivation of a strong evidence
ase (104).
.3.3. Pulmonary Hypertension in the
ardiac Surgical Patient
s the spectrum of cardiac surgical procedures—coronary
evascularization, valve repair and replacement, mechanical
ssist device implantation, and cardiac transplantation—has
een offered to an increasingly complex population of
atients, the importance of peri- and postoperative PH and
ight heart failure has become apparent. Often, PH is noted
reoperatively and appropriate therapy may be initiated
rior to surgery. Less commonly, it develops peri-
peratively without antecedent evidence of pulmonary vas-
ular disease or right heart failure. Outcomes are signifi-
antly worse in patients with perioperative PH and RV
ailure (218–220), prompting interest in the utility of newer
herapies for this situation, including PAH-specific thera-
ies. Little information has emerged thus far regarding the
tility of these therapies in this setting, and concern exists
egarding potential adverse effects should left-sided cardiac
lling pressures not be normalized following surgery.
.3.4. Preoperative Pulmonary Hypertension
ignificant PH has been reported in several patient popu-
ations in which cardiac surgery may be required, and it is
articularly common in patients with chronic mitral or
ortic valvular disease and in those with chronic severe left
eart failure (218–220). In the latter group, the presence of
ignificant PH with a high PVR may disqualify a patient
rom receiving an orthotopic cardiac transplantation. Re-
ersibility of the high PVR is often assessed by the admin-
stration of short acting pulmonary and systemic arterial
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Expert Consensus Document on Pulmonary Hypertension April 28, 2009:1573–619asodilators (221). Several reports describe the use of
hronic vasodilator agents or mechanical LV assistance to
ower PVR in patients with chronic left heart failure and
nitially fixed PH. Specific PAH therapies are rarely used in
atients with PH resulting from chronic valvular disease or
eft heart failure; the persistently elevated left-sided cardiac
lling pressures generally seen in these patients puts them at
isk for pulmonary edema when challenged with a selective
ulmonary vasodilator. Furthermore, studies have indicated
hat despite the adverse impact of PH on survival, surgical
ortic or mitral valve replacement and percutaneous mitral
alvuloplasty all have acceptable outcomes and frequently
esult in regression of PH (218,222,223).
.3.5. Postoperative Pulmonary Hypertension
H may persist following cardiac surgery despite successful
eduction of left-sided cardiac filling pressures to normal or
ear-normal levels. In this circumstance, initiation of PAH-
pecific therapy may be considered. It is advisable to
erform full RHC to ensure normalization of left-sided
ardiac filling pressures prior to beginning such treatment.
e novo PH following cardiac surgery is quite unusual.
Studies suggest that some patients with mitral stenosis
ave a significant rate of residual PH following successful
ercutaneous balloon valvuloplasty (223) or surgical com-
issurotomy or valve replacement (222). The incidence
ppears highest in patients with the greatest elevation of
VR preoperatively, and may be as high as 25% (223). PH
ay complicate aortic stenosis as well, and may also persist
ollowing surgical valve replacement (218). The incidence of
H following LV assist device implantation for chronic
evere heart failure is uncertain. One study suggested that
early 50% of such patients will have evidence of at least
ild PH acutely upon weaning from cardiopulmonary
ypass (224). PH is fairly common following cardiac trans-
lantation; the estimated incidence of at least mild PH has
een in excess of 60% (225). Severe PH following cardiac
ransplantation is rare, likely owing to aggressive preopera-
ive screening for fixed PH in transplant candidates.
A number of therapeutic strategies have been employed
or patients with PH with or without RV failure during and
ollowing cardiac surgery. In a population undergoing a
ariety of surgical interventions including coronary revascu-
arization, valve repair and replacement, mechanical assist
evice implantation, and cardiac transplantation, inhaled
O, given at a dose of 20 ppm for a mean of 36 hours,
mproved pulmonary and systemic arterial pressures and
ardiac index (226). Other studies have shown similar
enefits of NO in more homogenous populations with PH
ollowing valve surgery (227), ventricular assist device im-
lantation (224), and cardiac transplantation (228). On
alance, inhaled NO is an effective short-term strategy for
he management of PH following cardiac surgery. Inhaled
rostacyclin has also been used in patients with PH follow-
ng valve surgery (229). A head-to-head comparison of
nhaled prostacyclin and NO in this population found both mo be effective and to have better tolerability than intrave-
ous nitroprusside (230). Inhaled iloprost has been used
uccessfully in patients with PH and acute RV failure during
nd following cardiac transplantation (231). Sildenafil has
een reported to have beneficial hemodynamic effects when
dministered by nasogastric tube in patients undergoing
ardiac surgery who develop intraoperative PH (232).
For more persistent PH following cardiac surgery, oral
AH therapy may be considered. A small case series
uggested that oral sildenafil may be helpful in weaning
atients from intravenous or inhaled PAH therapy for PH
ollowing cardiac surgery (233). No clinical reports exist of
osentan used for this indication; however, a preclinical
tudy demonstrated its ability to prevent PH associated with
ardiopulmonary bypass (234).
.4. Summary of Recommendations
. Patients with PH require a thorough diagnostic eval-
uation to elucidate the roles of pulmonary venous
hypertension, chronic lung disease with hypoxemia,
and/or pulmonary thromboembolism to the patho-
genesis of their disease.
Accordingly, RHC, lung function and imaging studies,
etermination of arterial oxygen saturation (at rest, with
ctivity, and overnight), and ventilation-perfusion scanning
re all mandatory elements of the assessment of these
atients.
. Patients with PH related to pulmonary venous hyper-
tension may be considered for PAH-specific therapy
provided:
a. the cause of the pulmonary venous hypertension is
first optimally treated; and
b. the PCWP is normal or only minimally elevated; and
c. the transpulmonary gradient (TPG) and PVR are
significantly elevated; and
d. the patient’s symptoms suggest that PAH-specific
therapy may yield clinical benefit.
Treatment of such patients with PAH-specific therapy
hould be undertaken with great care, as these treatments
ay result in an increase in fluid retention, left-sided cardiac
lling pressures, and pulmonary edema, and result in clinical
eterioration. Decisions about whether and how to treat
uch patients should be made on a case by case basis by
xperienced PH caregivers.
. Patients with PH related to chronic lung disease and
hypoxemia may be considered for PAH-specific ther-
apy provided:
a. the chronic lung disease and hypoxemia are first
optimally treated; and
b. the TPG and PVR are significantly elevated; and
c. the patient’s symptoms suggest that PAH-specific
therapy may yield clinical benefit.
Treatment of such patients with PAH-specific therapy
hould be undertaken with great care, as these treatments
ay result in worsened hypoxemia and clinical deteriora-
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atients should be made on a case by case basis by
xperienced PH caregivers.
. Patients with chronic thromboembolic PH may be
considered for PAH-specific therapy provided:
a. appropriate secondary preventative measures, in-
cluding anticoagulation, has been instituted; and
b. PTE has been performed or is not indicated; and
c. the TPG and PVR are significantly elevated; and
d. the patient’s symptoms suggest that PAH-specific
therapy may yield clinical benefit.
Decisions about whether and how to treat such patients
hould be made on a case by case basis by experienced PH
aregivers.
. Patients with PH following cardiac surgery may be
considered for PAH-specific therapy provided:
a. the surgery and concomitant medical therapy pro-
vide optimal treatment of the underlying cardiac
disease; and
b. the surgery and concomitant medical therapy result
in a normal or only minimally elevated PCWP; and
c. the TPG and PVR remain significantly elevated; and
d. the patient’s clinical condition suggests that PAH-
specific therapy may yield clinical benefit.
Decisions about whether and how to treat such patients
hould be made on a case by case basis by experienced PH
aregivers.
0. Congenital Heart Disease-Related
ulmonary Arterial Hypertension
verall, the incidence of CHD is approximately 8 per 1,000
ive births (235).
Many different forms of CHD are associated with an
ncreased risk for the development of pulmonary vascular
isease (PVD). In patients with systemic-to-pulmonary
hunts, the type and size of the defect, as well as the
agnitude of the shunt, are risk factors for the development
f PAH. Shear stress due to increased pulmonary blood flow
nd/or increased pulmonary artery pressure appears to play
major role in the development of PVD related to CHD.
ased on natural history studies, approximately 30% of all
hildren born with CHD who do not undergo surgical
epair will develop PVD (235).
However, to date we have limited ability to determine
hich patients develop early irreversible PVD. There ap-
ears to be a difference between the pre- and post-tricuspid
hunt lesions. The laminar shear stress induced by the
ncrease in pulmonary blood flow alone may not be the same
s the laminar and circumferential pressure shear stress
nduced by post-tricuspid shunt lesions, for example, a
entricular septal defect. Patients with small- to moderate-
ized ventricular septal defects develop PVD in only approx-
mately 3% of cases; in contrast, almost all patients with an
nrepaired truncus arteriosus develop PVD, while approx- rmately 50% with a large ventricular septal defect and 10%
ith an atrial septal defect develop PVD. In addition, there
s significant biologic variability in the clinical presentation
nd prognosis. While some children with the same under-
ying CHD develop irreversible PVD in the first year of life,
thers with the same CHD may maintain acceptable levels
f pulmonary vascular resistance for many years. A recent
tudy demonstrated BMPR2 mutations in patients with
AH in CHD. Mutations in BMPR2 occur in patients
ith FPAH and IPAH. These data raise the possibility that
he presence of a genetic predisposition in some patients
ith CHD may contribute to the observed biologic vari-
bility (236). Further investigation into the role of genetic
utations may offer insight into which children with CHD
hould undergo surgical repair during early infancy. How-
ver, whether early therapeutic interventions halt or reverse
he progression of the PVD remains unclear.
Over the past several decades, advances in pediatric
ardiology/cardiac surgery have increased the number of
atients with CHD surviving into adulthood. However,
espite surgical correction of large systemic-to-pulmonary
hunts in infancy, surgical repair does not guarantee that
atients will not develop PVD postoperatively, and thus
lthough early diagnosis and improved cardiac surgery have
ignificantly decreased the number of patients overall with
isenmenger syndrome, some of these patients, for reasons
hat remain unclear, develop progressive PVD following
urgical repair. In addition to the symptoms and complica-
ions associated with PAH without Eisenmenger syndrome,
atients with Eisenmenger syndrome have additional co-
orbid conditions due to right-to-left shunting and hypox-
mia resulting in hematologic, hemostatic, cerebrovascular,
enal, rheumatologic, and cardiac complications.
With respect to therapeutic interventions, whether med-
cal or surgical, risk:benefit considerations need to be care-
ully evaluated based on the natural history of the condition
s well as on an individual basis. The survival and long term
utcome for patients with classic Eisenmenger syndrome is
uite different than for patients with other forms of PAH,
uch as IPAH/FPAH or PAH related to connective tissue
isease (72). Untreated, survival rates are 80% at 5 years and
pproximately 40% at 25 years. Despite the differences in
tiology and prognosis, PAH associated with CHD shares
imilarities with IPAH, for example, pulmonary vascular
istopathology. Based on these similarities, therapeutic
odalities demonstrated to be efficacious in patients with
PAH are beginning to be evaluated in patients with PAH
ssociated with CHD based on presumed similar pathobi-
logy. As opposed to patients with IPAH, in whom the
ikelihood of acute pulmonary vasoreactivity with effective
ong-term calcium channel blockade therapy is less than
0%, this is virtually nonexistent in patients with PAH
elated to CHD. To date, the only disease-specific targeted
AH therapy that has been demonstrated to be efficacious
n patients with PAH related to CHD is the ETA/ETB
eceptor antagonist bosentan. Although this trial was only
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atients with Eisenmenger syndrome in whom the natural
istory is significantly more protracted than for IPAH,
osentan improved exercise capacity and decreased pulmo-
ary vascular resistance without worsening systemic arterial
xygen saturation; the safety and tolerability profile was
omparable to that observed with previous PAH bosentan
rials (146). In addition, although not randomized con-
rolled trials, several open label uncontrolled studies have
eported improved exercise capacity and hemodynamics
including improvement in systemic arterial oxygen satura-
ion) with chronic intravenous epoprostenol (79,130). The
isk of complications with chronic intravenous epoproste-
ol, such as paradoxical emboli, needs to be carefully
eighed in patients with unrepaired or residual congenital
eart defects. Whether nonparenterally administered pro-
tanoids such as inhaled or oral prostanoids will prove to be
fficacious remains to be determined. In addition, whether
DE-5 inhibitors such as sildenafil will be efficacious in
atients with PAH/CHD will require further study.
1. Pediatric Pulmonary Arterial Hypertension
1.1. Persistent Pulmonary Hypertension
f the Newborn
ersistent pulmonary hypertension of the newborn (PPHN)
s a syndrome characterized by increased pulmonary vascular
esistance, right-to-left shunting, and severe hypoxemia.
PHN is frequently associated with pulmonary parenchy-
al abnormalities, including meconium aspiration, pneu-
onia, sepsis, lung hypoplasia, and alveolar capillary dys-
lasia. In some instances there is no evidence of pulmonary
arenchymal disease, and the etiology is unknown. Thus,
lthough PPHN is multifactorial in origin, the nature of the
nderlying defect(s) causing failure to adapt to extrauterine
ife is uncertain. This is not surprising, since the mecha-
isms responsible for achieving a normal fall in PVR at birth
re poorly understood. In the mature pulmonary circulation,
he interaction between healthy endothelial and smooth
uscle cells produces a balance between relaxation and con-
raction favoring relaxation due to release of endothelium-
erived NO. Whether failure to achieve the normal reduction
n PAP at birth is due to failure of endothelium-dependent
nd/or independent relaxation, a primary structural abnor-
ality of the pulmonary vascular smooth muscle cells, or an
xcess of vasoconstrictor agents such as endothelin or throm-
oxane remains unclear. Increased circulating endothelin-1
evels have been reported after birth in these neonates.
owever, the primary abnormality most likely varies with
arious risk factors similar to what is postulated for various
ther forms of PAH. The rationale for treating with inhaled
O and possibly a PDE-5 inhibitor such as sildenafil is due
o an absolute or relative lack of endogenous NO. Lung
ecruitment strategies facilitated by high frequency ventila-
ion may be particularly useful in enhancing the efficacy of dnhaled NO. Extracorporeal membrane oxygenation has
mproved survival for neonates with refractory hypoxemia,
lthough it may be associated with significant morbidity
i.e., hemorrhagic, neurologic, and other complications). The
fficacy of inhaled NO has also been demonstrated in multi-
enter randomized clinical trials, (i.e., improved oxygenation
nd reduction in the need for extracorporeal membrane oxy-
enation). However, despite the significant advances in treat-
ent strategies for PPHN, this condition continues to have an
nacceptably high morbidity and mortality rate of approxi-
ately 10% to 20%.
1.2. Pediatric Pulmonary Arterial Hypertension
ithout treatment, the natural history for children with
PAH is worse than in adults; however, with treatment, the
utcome appears better in children than in adults. Unfor-
unately, due to limited data in children with PAH, man-
gement decisions are often extrapolated from adult studies.
he selection of optimal therapy is complex, as there are no
onsistently successful treatments, and some agents may
nvolve complicated delivery systems, specific dosing regi-
ens, side effects, and potential complications. Further-
ore, if the disease progresses, the treatment may have to be
evised based on risk:benefit considerations.
In the absence of studies specifically reporting the clinical
esponse of children to PAH therapy, similar clinical strat-
gies have been suggested for the management of PAH in
hildren; however, without evidence-based data, these
uidelines must be used with caution. It should also be
ighlighted that children not infrequently have a very high
AP but remain in functional class II due to the absence of
V failure during childhood. Those with syncope or near
yncope, despite their functional class based on their level of
yspnea, should be treated aggressively, as one would treat a
unctional class IV patient. Based on expert consensus, the
nitial approach following the diagnosis of PAH in a child
s, in the absence of a contraindication, to treat the child
ith digitalis and diuretics, anticoagulation with warfarin,
nd supplemental oxygen if clinically indicated. Patients
ho are responders to acute vasoreactivity testing are also
reated with high-dose calcium channel blockade; nonre-
ponders and responders who remain functional class III are
onsidered for treatment with either an endothelin receptor
ntagonist, for example, bosentan, a PDE-5 inhibitor, for
xample, sildenafil, or a prostanoid, for example, inhaled
loprost. Functional class IV children and class III patients
ho do not improve with an endothelin receptor antagonist,
DE-5 inhibitor, or inhaled prostanoid should be consid-
red for treatment with an intravenous prostanoid, for
xample, epoprostenol/treprostinil. Due to differences in
etabolic activity in children versus adults, acute and
hronic pharmacokinetic studies are helpful to determine
ptimal dosing in children. With the advent of new drugs
ith targeted mechanisms of action, combination therapy may
ecome an attractive option for children who fail to improve or
eteriorate with a single agent; however, clinical data are
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April 28, 2009:1573–619 Expert Consensus Document on Pulmonary Hypertensionurrently limited. Finally, atrial septostomy and lung or heart-
ung transplantation can be considered for refractory PAH.
Based on similar pathobiology and pathophysiology in
hildren and adults with various forms of PAH, the con-
ensus amongst the PH community is that the diseases are
he same in children and in adults. The increased under-
tanding of FPAH further supports this, with genetic
nticipation highlighting the biologic variability that exists
n many forms of PAH. However, in IPAH, a significantly
reater percentage of children (up to 40%) are acute re-
ponders compared with adults, and the younger the child is
t the time of diagnosis, the greater the likelihood of acute
ulmonary vasoreactivity with acute vasodilator testing.
ncontrolled trials have reported that long-term adminis-
ration of high-dose calcium channel blockade prolongs
urvival in children, similar to that reported in adults (237).
owever, despite continued calcium channel blockade ther-
py, the benefit observed in IPAH children who are
esponders (97% 5-year survival) is not always preserved
ong term (10-year survival 81%) and treatment success at
0 years in children who are acute responders is less than
0% (238). Consequently, children who are acutely respon-
ive at diagnosis still have a significant risk for treatment
ailure long term on calcium channel blockade and need
lose follow-up. Serial reevaluation, including repeat acute
asodilator testing, is necessary in these children to maintain
n optimal therapeutic regimen.
Open label, uncontrolled studies with intravenous
poprostenol in IPAH children have demonstrated sus-
ained clinical and hemodynamic benefits for over 10 years.
ong-term intravenous epoprostenol has also been used
uccessfully in children with PAH associated with CHD,
mproving hemodynamics and quality of life parameters.
ata on bosentan therapy for PAH in children remain
imited. A retrospective analysis of 86 children with IPAH
r PAH-CHD demonstrated beneficial long-term effects of
osentan (alone or in combination with intravenous epopro-
tenol) on functional capacity, hemodynamics, and survival
n children with PAH (239). Subsequent analysis of the
ubgroup with PAH and CHD also demonstrated clinical
nd hemodynamic improvement similar to the experience
ith adult Eisenmenger patients.
Assessing safety and efficacy, particularly in young pedi-
tric patients, is problematic, that is, accurate assessment of
xercise capacity even in children old enough to exercise is
raught with difficulty. In addition, due to the biologic
ariability of PAH with the progressive nature more often
ore severe in the pediatric patients compared with adults,
thical issues become more problematic when considering
ong observational periods to assess overall morbidity and
ortality. Long-term safety issues are equally problematic
hen initiating therapy with unknown long-term safety
ffects in children. Thus, although clinical investigation with
hildren with PAH is more difficult and often approached
ithout enthusiasm, the potential rewards for having a signif-cant impact on overall quality of life as well as long-termurvival should far outweigh the difficulties and impediments in
eveloping improved therapeutic modalities for children.
2. Pulmonary Hypertension
enters of Excellence
AH is a rare disease with a high mortality. Given the
omplex nature of this disease, if at all possible, most
atients should be managed at or in conjunction with a
AH Center of Excellence. Centers that specialize in PAH
ffer physicians with expertise and experience in this com-
licated disease, nursing staff specially trained to assist in the
anagement of PAH patients and the complex therapies for
his disease, and often clinical trials of investigational agents.
ultidisciplinary programs enlist the expertise of both cardi-
logists and pulmonologists, and commonly rheumatologists,
epatologists, infectious disease specialists, hematologists,
ransplant physicians, psychologists, and social workers.
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